Introduction {#s1}
============

GE23077 (GE) is a cyclic-peptide antibiotic produced by the soil bacterium *Actinomadura* sp. DSMZ 13491 ([Figure 1A](#fig1){ref-type="fig"}; [@bib10]). GE exhibits antibacterial activity against both Gram-negative and Gram-positive bacterial pathogens in culture, including *Moraxella catarrhalis* and *Streptococcus pyogenes* ([Supplementary file 1A](#SD1-data){ref-type="supplementary-material"}; [@bib10]). GE inhibits both Gram-negative and Gram-positive bacterial RNA polymerase (RNAP) in vitro, but does not inhibit human RNAP I, II, or III in vitro ([Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}; [@bib10]). Analysis of the kinetics of inhibition suggests that GE inhibits RNAP at a stage subsequent to the formation of the RNAP-template complex ([@bib58]).10.7554/eLife.02450.003Figure 1.Mechanism of transcription inhibition by GE: inhibition of first nucleotide addition in transcription initiation.(**A**) Structure of GE. dmaDap, N^β^-(Z-2,3-dimethylacryloyl)-α,β-diaminopropionic acid; dhGln, β,γ-dihydroxy-glutamine; Ama, aminomalonic acid; aThr, allothreonine; iSer, isoserine. Wavy bonds, previously undefined stereochemistry. (**B**) GE does not inhibit formation of a transcription initiation complex. (**C**) GE inhibits nucleotide addition in transcription initiation (primer-dependent transcription initiation). (**D**) GE does not inhibit nucleotide addition in transcription elongation (elongation from halted TEC containing 29 nt RNA product). See [Figure 1---figure supplements 1, 2](#fig1s1 fig1s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.02450.003](10.7554/eLife.02450.003)10.7554/eLife.02450.004Figure 1---figure supplement 1.GE inhibits nucleotide addition in transcription initiation (*de novo* transcription initiation).**DOI:** [http://dx.doi.org/10.7554/eLife.02450.004](10.7554/eLife.02450.004)10.7554/eLife.02450.005Figure 1---figure supplement 2.GE does not inhibit nucleotide addition in transcription elongation (reconstituted transcription elongation complexes).**DOI:** [http://dx.doi.org/10.7554/eLife.02450.005](10.7554/eLife.02450.005)

GE is a non-ribosomally-synthesized cyclic heptapeptide ([Figure 1A](#fig1){ref-type="fig"}; [@bib40]). The stereochemistry at four chiral centers of GE has been defined based on acid hydrolysis and gas chromatography, but the stereochemistry at five other chiral centers has not been defined ([Figure 1A](#fig1){ref-type="fig"}; [@bib40]). Analogs of GE having modifications of the dmaDap, dhGln, and Ama residues, have been prepared by semi-synthetic derivatization of GE ([@bib42]).

Here we report the target and mechanism of transcription inhibition by GE. In addition, we report a series of crystal structures---including the first crystal structure of a substrate complex for de novo transcription initiation by a multisubunit RNAP---that define the structural relationships between GE and RNAP, GE and promoter DNA, GE and NTPs, and GE and rifamycins.

Our results show that GE inhibits RNAP through a novel binding site and novel mechanism. GE inhibits RNAP by binding to a site---the 'GE target'---that overlaps the RNAP active-center 'i' and 'i+1' sites and that includes coordinating ligands of the RNAP active-center catalytic Mg^2+^ ion, Mg^2+^(I). Binding of GE sterically precludes binding of initiating NTPs to the i site, i+1 site, and Mg^2+^(I), and thereby blocks transcription initiation. GE is the first identified example of a non-nucleoside RNAP inhibitor that functions through direct interaction with the core catalytic components of the RNAP active-center: the i site, i+1 site, and Mg^2+^(I).

Our results further show that the GE target has three features that make it an unusually attractive target---a 'privileged target'---for antibacterial drug discovery involving RNAP. First, the GE target includes functionally critical residues of the RNAP active center that cannot be substituted without loss of RNAP activity, and, therefore, that cannot be substituted to yield resistant mutants. Accordingly, the target-based resistance spectrum for GE is unusually small. Second, the GE target does not overlap the rifamycin target (the target of the most important RNAP inhibitors in current clinical use in antibacterial therapy; [@bib27]). Accordingly, GE exhibits no or negligible cross-resistance with rifamycins. Third, the GE target is immediately adjacent to the rifamycin target. Accordingly, it is possible to link GE to a rifamycin to construct a bipartite inhibitor that binds simultaneously to the GE target and the rifamycin target and, therefore, that is exceptionally potent and exceptionally refractory to target-based resistance.

Results {#s2}
=======

Mechanism of inhibition by GE: inhibition of first nucleotide addition in transcription initiation {#s2-1}
--------------------------------------------------------------------------------------------------

To define the mechanism of transcription inhibition by GE, we assessed effects of GE on individual reaction steps in transcription initiation and transcription elongation. [Figure 1B](#fig1){ref-type="fig"} shows that GE does not inhibit steps in transcription initiation up to and including formation of a competitor-resistant RNAP-promoter open complex (RP~o~). We infer that GE does not inhibit promoter binding, loading of promoter DNA into the RNAP active-center cleft, or promoter unwinding.

The results in [Figure 1C](#fig1){ref-type="fig"} show that GE inhibits nucleotide addition in transcription initiation. GE inhibits both primer-dependent transcription initiation ([Figure 1C](#fig1){ref-type="fig"}), and de novo transcription initiation ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). In primer-dependent transcription initiation, GE inhibits the first nucleotide-addition step, inhibiting the synthesis of a 3-nt RNA product from a 2-nt RNA primer and an NTP. In de novo transcription initiation, GE inhibits the first nucleotide-addition step, inhibiting the synthesis of a 2-nt RNA product from initiating NTPs.

The results in [Figure 1D](#fig1){ref-type="fig"} show that GE does not inhibit nucleotide addition in transcription elongation. GE does not inhibit transcription elongation upon addition of NTPs to a halted elongation complex ([Figure 1D](#fig1){ref-type="fig"}), and GE does not inhibit single nucleotide addition upon addition of an NTP to an elongation complex reconstituted from RNAP and a synthetic nucleic acid scaffold ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}).

We conclude that GE specifically inhibits nucleotide addition in transcription initiation. The observation that GE inhibits nucleotide addition in initiation but not in elongation suggests that GE functions through a binding site that is available in RP~o~ but that is not available in an elongation complex---for example, a binding site that overlaps the RNAP active-center i and i+1 nucleotide binding sites, or the path of the RNA product from the i and i+1 nucleotide binding sites, and that therefore would be unoccupied in RP~o~ but occupied by RNA in an elongation complex.

The mechanism of transcription inhibition of GE is reminiscent of, but differs from, the mechanism of transcription inhibition by rifampin (Rif) and other members of the rifamycin class. Like GE, Rif does not inhibit formation of RP~o~ ([Figure 1B](#fig1){ref-type="fig"}; [@bib44]). Also like GE, Rif inhibits nucleotide addition in transcription initiation, but does not inhibit nucleotide addition in transcription elongation ([Figure 1C,D](#fig1){ref-type="fig"}; [@bib68]). However, in contrast to GE, Rif does not generally inhibit the first nucleotide-addition step in transcription initiation ([Figure 1C](#fig1){ref-type="fig"}; [@bib44]). Rif generally only inhibits synthesis of \>2--3-nt RNA products and does so by binding to a site along the path of RNA from the RNAP active-center and sterically blocking RNA extension ([@bib6]; [@bib20]). The observation that GE inhibits synthesis of 2-nt RNA products, whereas Rif generally only inhibits synthesis of \>2--3-nt RNA products, suggests that GE functions through a binding site located closer than the Rif binding site to the RNAP active-center.

The mechanism of transcription inhibition by GE also differs from the mechanisms of transcription inhibition by other previously characterized RNAP inhibitors. Sorangicin (Sor) functions through the same binding site on RNAP as Rif and inhibits synthesis only of \>2--3-nt RNA products ([@bib7]). Myxopyronin (Myx), corallopyronin (Cor), ripostatin (Rip), and lipiarmycin (Lpm) inhibit formation of RP~o~ ([@bib27]). Streptolydigin (Stl), CBR703 (CBR), and microcin J25 (MccJ25) inhibit nucleotide addition in both initiation and elongation ([@bib2]; [@bib48]; [@bib27]). We conclude that GE inhibits transcription through a novel mechanism.

Target of inhibition by GE: RNAP active-center i and i+1 sites {#s2-2}
--------------------------------------------------------------

### Isolation and characterization of GE-resistant mutants {#s2-2-1}

To identify the target in RNAP for GE, we performed saturation mutagenesis of genes encoding *Escherichia coli* RNAP β and β′ subunits, and isolated and characterized mutants conferring GE-resistance (GE^R^). We performed saturation mutagenesis using a set of 'doped' oligonucleotide primers designed to introduce all possible nucleotide substitutions at all codons for all residues located within 30 Å of the RNAP active-center i and i+1 sites (primer sequences in [Supplementary file 2A](#SD2-data){ref-type="supplementary-material"}). We identified 33 independent single-substitution GE^R^ mutants ([Figure 2A](#fig2){ref-type="fig"}). All mapped to the RNAP β subunit ([Figure 2A](#fig2){ref-type="fig"}). The GE^R^ substitutions comprised six distinct substitutions at three sites in RNAP β: residues 565, 566, and 684 ([Figure 2A](#fig2){ref-type="fig"}). Minimal inhibitory concentration (MIC) assays indicate that all six GE^R^ substitutions result in at least moderate resistance (≥fourfold higher MIC) and that two result in high-level resistance (≥16-fold higher MIC; [Figure 2A](#fig2){ref-type="fig"}; [Supplementary file 2B](#SD2-data){ref-type="supplementary-material"}). Complementation assays indicate that each GE^R^ mutant is able to complement an *rpoB*^ts^ mutant for growth at the non-permissive temperature, indicating that each GE^R^ RNAP derivative is sufficiently functional in transcription to support viability ([Figure 2A](#fig2){ref-type="fig"}). RNAP purified from GE^R^ mutants exhibited resistance in vitro ([Figure 2B](#fig2){ref-type="fig"}), indicating that the GE^R^ phenotype at the cellular level is attributable to resistance at the enzymatic level. We conclude that RNAP is the functional cellular target for GE, and that RNAP β residues 565, 566, and 684 comprise a determinant essential for transcription inhibition by GE.10.7554/eLife.02450.006Figure 2.Target of transcription inhibition by GE: RNAP active-center i and i+1 sites.(**A**) GE^R^ mutants obtained following saturation mutagenesis of *E. coli rpoB* and *rpoC*. (**B**) GE^R^ phenotype of RNAP derivatives purified from GE^R^ mutants. (**C**) The GE target overlaps the RNAP active-center region. Structure of RNAP (gray ribbons; black circle for active-center region; violet sphere for Mg^2+^(I); β' non-conserved region and σ omitted for clarity; [@bib46]), showing sites of GE-resistant substitutions (green; sequences from A and [Supplementary file 2C](#SD2-data){ref-type="supplementary-material"}). Two orthogonal views. (**D**) The GE target does not overlap the Rif target. Structure of RNAP, showing sites of GE^R^ substitutions (green; sequences from A and [Supplementary file 2C](#SD2-data){ref-type="supplementary-material"}) and Rif^R^ substitutions (red; [@bib30]; [@bib63]). (**E**) GE^R^ mutants are not cross-resistant to Rif. (**F**) Rif^R^ mutants are not cross-resistant to GE. See [Figure 2---figure supplements 1, 2](#fig2s1 fig2s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.02450.006](10.7554/eLife.02450.006)10.7554/eLife.02450.007Figure 2---figure supplement 1.Location of GE target in sequence of RNAP β subunit.Sequence alignments for the β subunits of bacterial RNAP (top twenty-one sequences) and corresponding subunits of human RNAP I, RNAP II, and RNAP III (bottom three sequences), showing locations of GE^R^ substitutions in *E. coli* (black rectangles; sequences from [Figure 2A](#fig2){ref-type="fig"}) and *S. pyogenes* (black and gray rectangles; sequences in [Supplementary file 2C](#SD2-data){ref-type="supplementary-material"}). Species are as follows: *E. coli* (ECOLI), *Haemophilus influenzae* (HAEIN), *Vibrio cholerae* (VIBCH), *Pseudomonas aeruginosa* (PSEAE), *Treponema pallidum* (TREPA), *Borrelia burgdorferi* (BORBU), *Xylella fastidiosa* (XYLFA), *Campylobacter jejuni* (CAMJE), *Neisseria meningitidis* (NEIMA), *Rickettsia prowazekii* (RICPR), *Chlamydia trachomatis* (CHLTR), *Mycoplasma pneumoniae* (MYCPN), *Bacillus subtilis* (BACSU), *Staphylococcus aureus* (STAAU), *Streptococcus pyogenes* (STRP1), *Mycobacterium tuberculosis* (MYCTU), *Synechocystis sp.* PCC 6803 (SYNY3), *Aquifex aeolicus* (AQUAE), *Deinococcus radiodurans* (DEIRA), *Thermus thermophilus* (THETH), *Thermus aquaticus* (THEAQ), and *Homo sapiens* (HUMAN).**DOI:** [http://dx.doi.org/10.7554/eLife.02450.007](10.7554/eLife.02450.007)10.7554/eLife.02450.008Figure 2---figure supplement 2.Relationship between GE target and targets of other RNAP inhibitors.The GE target does not overlap the targets of Rif, Sor, Stl, CBR703, Myx, and Lpm. Structure of bacterial RNAP (gray ribbons; violet sphere for active-center Mg^2+^; β\' nonconserved region and σ omitted for clarity; [@bib46]), showing GE target (green; [Figure 2C](#fig2){ref-type="fig"}) and targets of Rif and Sor (red; [@bib53], [@bib54]; [@bib37]; [@bib30]; [@bib63], [@bib64]; [@bib22], [@bib7]; [@bib82]; [@bib55]; ES and RHE, unpublished), Stl (yellow; [@bib38]; [@bib24]; [@bib61]; [@bib75]), CBR703 (blue; [@bib2]; X Wang and RHE, unpublished), Myx (magenta; [@bib46]), and Lpm (cyan; [@bib15]; [@bib70]; RY Ebright, DD, and RHE, unpublished). Views as in [Figure 2C](#fig2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.02450.008](10.7554/eLife.02450.008)

Analysis of a panel of *Streptococcus pyogenes* mutants carrying single-substitutions within the RNAP active-center region indicates that substitutions at residues corresponding to *E. coli* RNAP β residues 565, 681, and 684 confer a GE^R^ phenotype ([Supplementary file 2C](#SD2-data){ref-type="supplementary-material"}). We conclude that the region comprising RNAP β residues 565-566 and 681-684 constitutes a determinant essential for transcription inhibition by GE in both Gram-negative and Gram-positive bacterial RNAP.

The sites of GE^R^ substitutions are conserved in RNAP from both Gram-negative and Gram-positive bacteria ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). This is consistent with, and accounts for, the observation that GE inhibits RNAP from both Gram-negative and Gram-positive bacteria ([Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}). Two sites of GE^R^ substitutions, β residues 681 and 684, are not conserved in human RNAP I, II, and III ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). This is consistent with, and accounts for, the observation that GE does not inhibit human RNAP I, II, and III ([Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}; [@bib10]).

### GE target {#s2-2-2}

In the three-dimensional structure of RNAP, the sites of GE^R^ substitutions are located adjacent to each other and form a compact determinant ('GE target'; [Figure 2C](#fig2){ref-type="fig"}). The GE target is located in the RNAP active-center region ([Figure 2C](#fig2){ref-type="fig"}). The GE target overlaps the RNAP active-center i and i+1 nucleotide binding sites, and comprises residues in two active-center subregions: the 'D2 loop' and the 'link region' ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). The RNAP active center contains two nucleotide binding sites---the i site and the i+1 site\--flanking the catalytic Mg^2+^ ion, Mg^2+^(I) ([@bib83]). The i site serves as the binding site for the first initiating NTP in de novo transcription initiation, and as the binding site for the 3′-nucleotide of the RNA primer in primer-dependent transcription initiation and RNA product in transcription elongation. The i+1 site serves as the binding site for the second initiating NTP in de novo transcription initiation, and as the binding site for the extending NTP in primer-dependent transcription initiation and transcription elongation ([@bib83]). The D2 loop and the link region play roles in nucleotide addition, transcriptional fidelity, and transcriptional pausing ([@bib36]; [@bib35]; [@bib74]; [@bib79], [@bib80]; [@bib23]). The location of the GE target suggests that GE inhibits RNAP through direct interference with the function of the i and i+1 nucleotide binding sites and/or of Mg^2+^(I).

The GE target is located approximately midway between Mg^2+^(I) and the Rif target ([Figure 2C,D](#fig2){ref-type="fig"}). The location is consistent with the hypothesis of the preceding section that the inhibition of the first nucleotide-addition step by GE, but only of subsequent nucleotide-addition steps by Rif, is attributable to the closer proximity of the GE binding site to the RNAP active-center.

### Relationship between GE target and targets of previously characterized RNAP inhibitors {#s2-2-3}

The GE target is located adjacent to, but does not overlap, the Rif target ([Figure 2D](#fig2){ref-type="fig"}). Consistent with the absence of overlap, GE^R^ mutants do not exhibit cross-resistance with Rif ([Figure 2E](#fig2){ref-type="fig"}; [Supplementary file 2D](#SD2-data){ref-type="supplementary-material"}), and, conversely, Rif^R^ mutants do not exhibit cross-resistance with GE ([Figure 2F](#fig2){ref-type="fig"}; [Supplementary file 2E](#SD2-data){ref-type="supplementary-material"}; [@bib10]).

The GE target also does not overlap the targets of the previously characterized RNAP inhibitors Sor, Myx, Cor, Rip, Lpm, Stl, and CBR703 ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Accordingly, GE^R^ mutants exhibit no cross-resistance with Sor, Myx, Cor, Rip, Lpm, Stl, and CBR703 ([Supplementary file 2F](#SD2-data){ref-type="supplementary-material"}).

### Unusually small size of GE target {#s2-2-4}

The GE target is strikingly small. The GE target comprises only six substitutions and only three sites in *E. coli* RNAP ([Figure 2A](#fig2){ref-type="fig"}), and has dimensions of just ∼16 Å × ∼10 Å × ∼9 Å ([Figure 2C](#fig2){ref-type="fig"}). The GE target is much smaller than the Rif target (71 substitutions and 27 sites; ∼30 Å × ∼25 Å × ∼10 Å; [Figure 2D](#fig2){ref-type="fig"}; [@bib30]; [@bib63]). The GE target also is much smaller than the targets of other RNAP inhibitors, including the Myx/Cor/Rip target (28 substitutions and 19 sites; [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}; [@bib46]), the Lpm target (30 substitutions and 20 sites; [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}; [@bib70]; DD, and RHE, unpublished), the Stl target (27 substitutions and 19 sites; [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}; [@bib75]), the CBR703 target (23 substitutions and 13 sites; [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}; [@bib2]; X Wang and RHE, unpublished), and the MccJ25 target (86 substitutions and 52 sites; [@bib48]). The GE target also is small relative to the size of GE. We infer that the genetically defined GE target corresponds to just part of the GE binding site on RNAP, not the full GE binding site on RNAP (in contrast to the genetically defined targets of Rif and other previously characterized RNAP inhibitors, which correspond to full inhibitor binding sites; [@bib27]). Specifically, we infer that the GE binding site comprises not only the residues at which GE^R^ substitutions are obtained, but also evolutionarily invariant, functionally essential, residues of the RNAP active center that cannot be substituted without loss of RNAP function, and thus cannot be substituted to confer GE-resistance. According to this hypothesis, the full GE binding site on RNAP includes not only the genetically-defined GE target, but also the full, or nearly the full, active-center i and i+1 sites; and GE bound to its target would be positioned to interfere directly, through steric clash, with function of the i and i+1 sites and/or Mg^2+^(I).

The unusually small size of the GE target-based resistance spectrum (six substitutions at three sites in *E. coli*; ∼1/10 the size of the target-based resistance spectrum for Rif, and ∼1/10 to ∼1/5 the sizes of the target-based resistance spectra for other RNAP inhibitors) has a potentially important practical implication. Namely, the frequency of spontaneous mutations yielding target-dependent GE-resistance is expected to be unusually small (∼1/10 to ∼1/5 the frequency of spontaneous mutations yielding target-dependent resistance to Rif and other RNAP inhibitors). In view of the fact that spontaneous mutations yielding target-dependent Rif-resistance are a major problem in antibacterial therapy with Rif ([@bib27]), the smaller size of the GE target-based resistance spectrum is a potentially important advantage.

Structural basis of inhibition by GE: crystal structure of RNAP-GE {#s2-3}
------------------------------------------------------------------

### GE binds to the GE target {#s2-3-1}

To define the structural basis of transcription inhibition by GE, we determined a crystal structure of *Thermus thermophilus* RNAP holoenzyme in complex with GE at 3.35 Å resolution ([Figure 3](#fig3){ref-type="fig"}). [Figure 3A](#fig3){ref-type="fig"} shows that GE binds to the genetically-defined GE target, confirming the hypothesis that the GE target represents a determinant for binding of GE to RNAP. The structure shows that GE occupies the RNAP i and i+1 sites and makes direct interactions with the D2 loop, the link region, and an RNAP Asp residue and water molecule that coordinate Mg^2+^(I) ([Figure 3B--E](#fig3){ref-type="fig"}). The structure provides strong support to the hypothesis that GE inhibits RNAP by directly interfering with function of the i and i+1 sites and/or Mg^2+^(I).10.7554/eLife.02450.009Figure 3.Structural basis of transcription inhibition by GE: crystal structure of RNAP-GE.(**A**) Overall structure. Green, GE; violet sphere, Mg^2+^(I); yellow, σ. (**B**) Crystallographic data and refinement statistics. (**C**) Electron density and atomic model for GE. Blue mesh, mF~o~-DF~c~ omit map for GE (contoured at 2.5σ); blue sticks, GE; gray ribbons, RNAP backbone; green surfaces, RNAP residues at which substitutions confer GE-resistance ([Figure 2A](#fig2){ref-type="fig"}; [Supplementary file 2C](#SD2-data){ref-type="supplementary-material"}); cyan sticks, additional RNAP residues that contact GE; gray and red sticks additional RNAP residues that coordinate Mg^2+^(I); violet sphere, Mg^2+^(I). D2, LR, H, I, Mg^2+^, and BH denote the RNAP D2 loop, link region, H region, I region, Mg^2+^ loop, and bridge helix. RNAP residues are numbered both as in *T. thermophilus* RNAP and as in *E. coli* RNAP (in parentheses). (**D**) Contacts between RNAP and GE (stereodiagram). Gray ribbons, RNAP backbone; gray sticks, RNAP carbon atoms; green, GE carbon atoms; red, oxygen atoms; blue, nitrogen atoms; red spheres, water molecules; violet sphere, Mg^2+^(I). Blue dashed lines, H-bonds; orange dashed lines, coordinate-covalent bonds. (**E**) Contacts between RNAP and GE (schematic). Red dashed lines, H-bonds; orange dashed lines, coordinate-covalent bonds; blue arcs, van der Waals interactions; W, water molecule. See [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.02450.009](10.7554/eLife.02450.009)10.7554/eLife.02450.010Figure 3---figure supplement 1.Structural basis of transcription inhibition by GE.Location of contacting residues in the sequences of RNAP β subunit (top) and RNAP β\' subunit (bottom). Sequence alignments for the β and β\' subunits of bacterial RNAP (top twenty-one sequences in each panel) and corresponding subunits of human RNAP I, RNAP II, and RNAP III (bottom three sequences in each panel), showing locations of residues that contact GE in the crystal structure of RNAP-GE (black rectangles; identities from [Figure 3E](#fig3){ref-type="fig"}), and locations of the RNAP D2 loop, link region, H region, I region, Mg^2+^ loop, and bridge helix (black bars; boundaries from [@bib72] and [@bib79]). Species names are as in [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.02450.010](10.7554/eLife.02450.010)

### RNAP residues at which GE-resistance substitutions occur contact GE {#s2-3-2}

All residues at which GE^R^ substitutions were obtained make direct contact with GE in the crystal structure: βGlu565, βGly566, βMet681, and βAsn684 (green in [Figure 3C](#fig3){ref-type="fig"}). (Here and elsewhere in the text, residues are numbered as in *E. coli* RNAP. In [Figures 3--5](#fig3 fig4 fig5){ref-type="fig"}, residues are numbered both as in *T. thermophilus* RNAP and as in *E. coli* RNAP.) The sidechain of βGlu565 penetrates the GE macrocycle and makes interactions with six of seven GE residues ([Figure 3C--E](#fig3){ref-type="fig"}). Substitution of βGlu565 is expected to disrupt multiple H-bonds and van der Waals interactions between RNAP and GE. Substitution of βGly566 by any residue other than Gly is expected to introduce steric clash between RNAP and GE. Substitution of βMet681 is expected to disrupt van der Waals interactions between RNAP and GE. Substitution of βAsn684 is expected to disrupt H-bonds and van der Waals interactions between RNAP and GE.

### Additional RNAP residues contact GE {#s2-3-3}

Besides the residues at which GE^R^ substitutions were obtained, 11 additional residues---all located in the RNAP active-center i and i+1 sites---make direct interactions with GE in the crystal structure: βPro564, βAsn568, βArg678, βMet685, βGln688, βLys1065, βLys1073, βHis1237, β′Asp462, β'Thr786, and β'Ala787 (cyan in [Figure 3C](#fig3){ref-type="fig"}). 10 of these additional residues are invariant in RNAP from bacteria to humans ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), and, for six, it is known that substitutions result in a loss of RNAP function ([@bib32]; [@bib49]; [@bib56]; [@bib69]; [@bib31]). We infer that these additional residues cannot be substituted without loss of RNAP function, and thus cannot be substituted to give rise to GE-resistance.

### GE stereochemistry {#s2-3-4}

The experimental electron density and inferred bonding patterns in the crystal structure define the stereochemistry at the five previously unassigned stereocenters of GE, as follows: D-dmaDap, D-Ser, D-Val, 3R,4S,L-dhGln, D-aThr, D-iSer, and L-Ama ([Figure 3C--E](#fig3){ref-type="fig"}). The assignment of stereochemistry at dhGln C3 is tentative. The assignments of stereochemistry at other stereocenters are firm.

### RNAP-GE interactions {#s2-3-5}

The crystal structure also defines the orientation of GE relative to RNAP and the interactions between GE and RNAP ([Figure 3C--E](#fig3){ref-type="fig"}). GE binds within a shallow bowl-like depression formed by the D2 loop, the link region, and the Mg^2+^ loop \[Mg^2+^(I) and three RNAP Asp residues that coordinate Mg^2+^(I)\], and the H and I regions ([Figure 3C,D](#fig3){ref-type="fig"}). GE is oriented relative to RNAP such that the GE dhGln residue is directed toward Mg^2+^(I) and the GE dmaDap residue is directed toward the Rif pocket ([Figure 3C--E](#fig3){ref-type="fig"}).

The GE dhGln residue participates in a network of interactions, including H-bonds with RNAP βGlu565, βArg678, and βLys1073, an H-bond with a water molecule in the first coordination shell of Mg^2+^(I), and van der Waals interactions with RNAP β′Asp462, which is one of the three RNAP Asp residues that coordinate Mg^2+^(I) ([Figure 3D--E](#fig3){ref-type="fig"}). The GE aThr residue makes an H-bond with RNAP βLys1065 and van der Waals interactions with βGlu565, βMet685, βLys1073, and βHis1237. The GE iSer residue makes H-bonds with RNAP βGlu565, βAsn684, and βGln688, and van der Waals interactions with βMet681. The GE Ama residue makes H-bonds with RNAP βGlu565 and βGln688, and van der Waals interactions with βAsn684. The GE dmaDap residue makes an H-bond with RNAP βAsn568 and van der Waals interactions with βGly566 and βPro564. Atoms of the GE dmaDap sidechain distal to the sidechain carbonyl are disordered in the structure, indicating that these atoms exhibit static or dynamic conformational heterogeneity, and suggesting that these atoms make few or no interactions with RNAP (omitted in [Figure 3C--D](#fig3){ref-type="fig"}; gray in [Figure 3E](#fig3){ref-type="fig"}). The GE Ser residue makes van der Waals interactions with RNAP βGlu565. The GE Val residue makes van der Waals interactions with RNAP βGlu565, β′Thr786, and β'Ala787.

The structure accounts for the structure-activity relationships obtained from analysis of semi-synthetic derivatives of GE. Modification of the GE dhGln sidechain eliminates RNAP-inhibitory activity ([@bib42]), consistent with the participation by this sidechain in multiple H-bonds and van der Waals interactions with RNAP. Removal of the Ama sidechain reduces RNAP-inhibitory activity ([@bib42]), consistent with the participation of this sidechain in an H-bond and van der Waals interactions with RNAP. Substitutions of the dmaDap sidechain acyl moiety, including substitutions with bulky groups, has little or no effect on RNAP-inhibitory activity ([@bib42]), consistent with the fact that atoms of the acyl group are disordered in the structure and are inferred to make few or no interactions with RNAP.

Structural basis of inhibition by GE: crystal structure of RP~o~-GE {#s2-4}
-------------------------------------------------------------------

To define effects of GE on interactions of RNAP with promoter DNA, we determined a crystal structure of RP~o~ in complex with GE at 2.8 Å resolution ([Figure 4](#fig4){ref-type="fig"}). The higher resolution of this structure (2.8 Å vs 3.35 Å) enables confirmation of the inferred stereochemical assignments at stereocenters of GE ([Figure 4D,E](#fig4){ref-type="fig"}) and enables identification of additional water-mediated H-bonds, including additional water-mediated H-bonds in the network of water-mediated interactions connecting GE to Mg^2+^(I) ([Figure 4D--E](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}).10.7554/eLife.02450.011Figure 4.Structural basis of transcription inhibition by GE: crystal structure of RP~o~-GE.(**A**) Overall structure. (**B**) Crystallographic data and refinement statistics. (**C**) Electron density and atomic model for GE. (**D**) Contacts between RP~o~ and GE (stereodiagram). (**E**) Contacts between RP~o~ and GE (schematic). See [Figure 4---figure supplements 1, 2](#fig4s1 fig4s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.02450.011](10.7554/eLife.02450.011)10.7554/eLife.02450.012Figure 4---figure supplement 1.Structural basis of transcription inhibition by GE.Network of contacts to GE dhGln residue. Stereoview. Gray, RNAP carbon atoms. Green, GE carbon atoms. Red, oxygen atoms. Blue, nitrogen atoms. Violet sphere, Mg^2+^(I). Red spheres, water molecules. Dashed blue lines, H-bonds. Dashed orange lines, coordinate-covalent bonds.**DOI:** [http://dx.doi.org/10.7554/eLife.02450.012](10.7554/eLife.02450.012)10.7554/eLife.02450.013Figure 4---figure supplement 2.Absence of effects of DNA on GE conformation and RNAP-GE interactions.Superimposition of crystal structures of RP~o~-GE ([Figure 4](#fig4){ref-type="fig"}) and RNAP-GE ([Figure 3](#fig3){ref-type="fig"}). Blue mesh, blue sticks, red sticks, gray surface, yellow surface, and violet sphere: mF~o~-DF~c~ omit map for GE, atomic model for GE, DNA, RNAP, σ, and Mg^2+^(I) from crystal structure of RP~o~-GE ([Figure 4](#fig4){ref-type="fig"}). Cyan sticks, atomic model for GE from crystal structure of RNAP-GE ([Figure 3](#fig3){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.02450.013](10.7554/eLife.02450.013)10.7554/eLife.02450.014Figure 4---figure supplement 3.Absence of effects of GE on DNA conformation and RNAP-DNA interactions.Superimposition of crystal structures of RP~o~-GE ([Figure 4](#fig4){ref-type="fig"}) and RP~o~ ([@bib84]). Blue mesh, blue sticks, red sticks, gray surface, yellow surface, and violet sphere: mF~o~-DF~c~ omit map for GE, atomic model for GE, DNA, RNAP, σ, and Mg^2+^(I) from crystal structure of RP~o~-GE ([Figure 4](#fig4){ref-type="fig"}). Cyan sticks, DNA from crystal structure of RP~o~ ([@bib84]).**DOI:** [http://dx.doi.org/10.7554/eLife.02450.014](10.7554/eLife.02450.014)

Comparison of the structures of RNAP-GE ([Figure 3](#fig3){ref-type="fig"}) and RP~o~-GE ([Figure 4](#fig4){ref-type="fig"}) shows that promoter DNA binding to form RP~o~ does not change the conformation of GE or the interactions between RNAP and GE ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Comparison of structures of RP~o~ ([@bib84]) and RP~o~-GE ([Figure 4](#fig4){ref-type="fig"}) show that GE does not change the conformation of DNA or the interactions between RNAP and DNA ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). The results provide a graphic confirmation of the results from [Figure 1](#fig1){ref-type="fig"}, indicating that GE does not inhibit formation of RP~o~ and, instead, inhibits a subsequent reaction required for the first nucleotide addition in transcription initiation.

Relationship between GE and initiating nucleotides: mutually exclusive binding {#s2-5}
------------------------------------------------------------------------------

### Structural modelling of steric clash between GE and initiating nucleotides {#s2-5-1}

As a first step to assess whether occupancy of the RNAP i and i+1 sites by GE interferes with the binding of nucleotides to the i and i+1 sites, we constructed a structural model of a primer-dependent transcription initiation complex by superimposing crystal structures of RP~o~-GE ([Figure 4](#fig4){ref-type="fig"}), RP~o~ in complex with a 2-nt RNA primer occupying the i-1 and i sites ([@bib84]), and a transcription elongation complex containing an NTP in the i+1 site ([@bib77]) ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). The resulting structural model predicts severe steric clash between GE and both the RNA 3′ nucleotide in the i site and the NTP in the i+1 site ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). The phosphate and base of the RNA 3′ nucleotide are predicted to clash with the aThr residue and Ama residue, respectively, of GE. The α-phosphate and base of the NTP in the i+1 site are predicted to clash with the dhGln residue and Val residue, respectively, of GE. The structural model strongly suggests that GE interferes with binding of nucleotides to the RNAP i and i+1 sites.

### Crystal structure defining interactions between RP~o~ and initiating nucleotides in the absence of GE {#s2-5-2}

As a second step to assess whether occupancy of the RNAP i and i+1 sites by GE interferes with the binding of nucleotides to the i and i+1 sites, and, in order to define how the triphosphate of the first initiating NTP interacts with RNAP and how interactions may be impacted by GE, we determined a crystal structure of RP~o~ in complex with initiating NTPs at 3.1 Å resolution ([Figure 5A--D](#fig5){ref-type="fig"}). To determine the structure, we soaked a pre-formed crystal of RP~o~ with the first initiating NTP (ATP) and a non-reactive analog of the second initiating NTP (CMPcPP). The electron density map shows unambiguous electron density for ATP in the i site and for CMPcPP:Mg^2+^(II) in the i+1 site ([Figure 5B](#fig5){ref-type="fig"}). The resulting structure provides the first structural information of a substrate complex for de novo transcription by a multi-subunit RNAP.10.7554/eLife.02450.015Figure 5.Relationship between GE and initiating NTPs: mutually exclusive binding.(**A**) Crystal structure of RP~o~-ATP-CMPcPP: crystallographic data and refinement statistics. (**B**) Crystal structure of RP~o~-ATP-CMPcPP: electron density and model. Green mesh, mF~o~-DF~c~ omit map for ATP and CMPcPP:Mg^2+^(II) (contoured at 2.5σ); pink sticks, ATP and CMPcPP; red ribbon, DNA template strand; gray ribbon, RNAP bridge helix; upper and lower violet spheres, Mg^2+^(I) and Mg^2+^(II). (**C**) Crystal structure of RP~o~-ATP-CMPcPP: contacts between RNAP and initiating NTPs (stereodiagram). Gray ribbon, RNAP bridge helix; gray sticks, RNAP carbon atoms; continuous red sticks, DNA atoms; pink sticks, ATP and CMPcPP carbon atoms; individual red sticks, oxygen atoms; individual blue sticks, nitrogen atoms; red spheres, water molecules; upper and lower violet spheres, Mg^2+^(I) and Mg^2+^(II). Blue dashed lines, H-bonds; orange dashed lines, coordinate-covalent bonds. (**D**) Crystal structure of RP~o~-ATP-CMPcPP: contacts between RNAP and initiating NTPs (schematic summary). Red dashed lines, H-bonds; orange dashed lines, coordinate-covalent bonds; blue arcs, van der Waals interactions; W, water molecule; underlined residues, GE-contacting residues in RP~o~-GE. (**E**) Superimposition of crystal structures of RP~o~-GE and RP~o~-ATP-CMPcPP: inferred steric clash between GE and initiating NTPs. Blue mesh, blue sticks, red sticks, and gray ribbon: mF~o~-DF~c~ omit map for GE, atomic model for GE, DNA template strand, and RNAP bridge helix from RP~o~-GE ([Figure 4](#fig4){ref-type="fig"}). Pink sticks and violet spheres: ATP, CMPcPP, Mg^2+^(I), and Mg^2+^(II) from RP~o~-ATP-CMPcPP. (**F**) Crystal structure of RP~o~-GE plus ATP and CMPcPP: crystallographic data and refinement statistics. (**G**) Crystal structure of RP~o~-GE plus ATP and CMPcPP: electron density and model. Blue mesh, mF~o~-DF~c~ omit map for GE (contoured at 2.7σ); blue sticks, GE; green mesh, mF~o~-DF~c~ omit map for NTP triphosphate:Mg^2+^(II) in RNAP E site (contoured at 2.7σ); pink sticks, NTP triphosphate; thin pink sticks, NTP sugar and base (projected); red ribbon, DNA template strand; gray ribbon, RNAP bridge helix; upper and lower violet spheres, Mg^2+^(I) and Mg^2+^(II). See [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.02450.015](10.7554/eLife.02450.015)10.7554/eLife.02450.016Figure 5---figure supplement 1.Relationship between GE and initiating NTPs.Superimposition of crystal structures of RP~o~-GE, RP~o~-GpA, and the transcription elongation complex: predicted steric clash between GE and NTPs in i and i+1 sites. Blue mesh, blue sticks, red sticks, gray ribbon: mF~o~-DF~c~ omit map for GE, atomic model for GE, DNA template strand, and RNAP bridge helix from crystal structure of RP~o~-GE ([Figure 4](#fig4){ref-type="fig"}). Upper pink sticks and violet sphere: RNA 3\' nucleotide in i site and Mg^2+^(I) from crystal structure of RP~o~-GpA ([@bib84]). Lower pink sticks and violet sphere: NTP in i+1 site and Mg^2+^(II) from crystal structure of the transcription elongation complex ([@bib77]).**DOI:** [http://dx.doi.org/10.7554/eLife.02450.016](10.7554/eLife.02450.016)

The base and sugar moieties of the first initiating NTP make the same interactions with DNA and RNAP that the RNA 3′-nucleotide base and sugar make in a transcription elongation complex ([@bib77]; [Figure 5C,D](#fig5){ref-type="fig"}). The triphosphate of the first initiating NTP extends into the space that is occupied by the RNA-1 nucleotide in a transcription elongation complex, and makes H-bonds and salt-bridges through its γ-phosphate with RNAP βGln688 and βHis1237, and through its α-phosphate with RNAP βLys1065 and βLys1073 ([Figure 5C,D](#fig5){ref-type="fig"}). The observed interactions of the γ-phosphate and α-phosphate with βHis1237 and βLys1065 are consistent with, and account for, crosslinking results ([@bib49]).

The base moiety of the second initiating NTP makes the same interactions with DNA and RNAP that the extending NTP base makes in an elongation complex ([@bib77]; [Figure 5C,D](#fig5){ref-type="fig"}). The sugar and triphosphate of the second initiating NTP make interactions characteristic of a 'preinsertion-mode' elongation complex, in which the sugar and triphosphate make only a subset of the interactions required for catalysis, and, in particular, in which the triphosphate approaches, but does not coordinate, Mg^2+^(I) ([@bib77]; [@bib83]; [@bib43]; [Figure 5C,D](#fig5){ref-type="fig"}). The RNAP active center is not fully dehydrated and contains two ordered water molecules in the interface between the first and second initiating NTPs (red spheres in [Figure 5C](#fig5){ref-type="fig"}; 'W' in [Figure 5D](#fig5){ref-type="fig"}), consistent with expectation for a 'preinsertion-mode' complex. The RNAP trigger loop, which can adopt open or closed conformational states, adopts an open conformational state in this structure, further consistent with expectation for a 'preinsertion-mode' complex. It is believed that the 'preinsertion-mode' elongation complex is an obligatory functional intermediate in formation of the catalytically competent 'insertion-mode' elongation complex ([@bib77]; [@bib83]; [@bib43]). We suggest, by analogy, that the 'preinsertion-mode' initiation complex defined herein is an obligatory functional intermediate in formation of the catalytically competent 'insertion-mode' initiation complex.

The determination of a crystal structure of a substrate complex for de novo initiation ([Figure 5A--D](#fig5){ref-type="fig"}) provided a firm foundation for structural modelling of relationships between GE and initiating nucleotides in a transcription initiation complex. Accordingly, we constructed a structural model by superimposing crystal structures of RP~o~-GE ([Figure 4](#fig4){ref-type="fig"}) and RP~o~-ATP-CMPcPP ([Figure 5A--D](#fig5){ref-type="fig"}). The resulting structural model shows severe steric clash between GE and both the first initiating NTP in the i site and the second initiating NTP in the i+1 site ([Figure 5E](#fig5){ref-type="fig"}). The structural model confirms the steric clashes predicted in the structural model built using an elongation complex structure ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), and reveals new, particularly severe, steric clashes involving the triphosphate of the first initiating NTP ([Figure 5E](#fig5){ref-type="fig"}). The steric clashes with the triphosphate entail essentially complete steric interpenetration of the triphosphate α, β, and γ phosphates with the GE aThr and Ama residues. The structural model very strongly suggests that GE interferes with binding of nucleotides to the RNAP i and i+1 sites.

### Crystal structure defining interactions between RP~o~ and initiating nucleotides in the presence of GE {#s2-5-3}

To test directly whether GE interferes with binding of initiating NTPs to the i and i+1 sites, we compared NTP occupancies of the i and i+1 sites in the absence of GE to those in the presence of GE. To do this, we compared electron density maps for crystals of RP~o~ soaked with ATP and CMPcPP ([Figure 5A,B](#fig5){ref-type="fig"}) to electron density maps for crystals of RP~o~ first soaked with GE and then soaked with ATP and CMPcPP ([Figure 5F,G](#fig5){ref-type="fig"}). As described above, electron density maps obtained by soaking a crystal of RP~o~ with ATP and CMPcPP show unambiguous electron density for ATP and CMPcPP in the i and i+1 sites ([Figure 5B](#fig5){ref-type="fig"}). In contrast, electron density maps obtained by soaking a crystal of RP~o~ first with GE, and then with ATP and CMPcPP show unambiguous electron density for GE, but show no density for ATP or CMPcPP in the i and i+1 sites ([Figure 5G](#fig5){ref-type="fig"}). Instead, electron density attributable to an NTP triphosphate is seen in a region adjacent to the i+1 site termed the 'E site' ([Figure 5G](#fig5){ref-type="fig"}). The E site previously has been reported as a binding site for a non-complementary NTP and has been proposed to serve as an entry site for NTPs on the pathway of NTP binding ([@bib81]). The pair of structures indicating that initiating NTPs occupy the i and i+1 sites in the absence of GE ([Figure 5B](#fig5){ref-type="fig"}), but do not occupy the i and i+1 sites in the presence of GE ([Figure 5G](#fig5){ref-type="fig"}), show graphically that GE interferes with binding of initiating NTPs to the i and i+1 sites.

In further work, we performed analogous crystal-soaking experiments to assess effects of GE on occupancy of 3′-deoxy-3′-amino-ATP and CTP (a non-reactive analog of the first initiating NTP and a reactive second initiating NTP) and of ATP and CTP (a reactive first initiating NTP and a reactive second initiating NTP). In these cases, soaking of nucleotides into RP~o~ in the absence of GE yielded, respectively, an 'insertion mode' substrate complex with nucleotides in the i and i+1 sites, and a product complex with a 2-nt RNA product (to be published elsewhere). In contrast, in each case, soaking nucleotides into RP~o~ pre-soaked with GE yielded a complex with electron density for GE, no electron density for nucleotides in the i and i+1 sites, and density attributable to an NTP triphosphate in the E site.

We conclude that GE interferes with binding of initiating nucleotides to the RNAP i and i+1 sites.

Relationship between GE and Rif: simultaneous binding {#s2-6}
-----------------------------------------------------

### Partial-competitive binding of GE and Rif {#s2-6-1}

The observation that the GE target is adjacent to the Rif target ([Figure 2D](#fig2){ref-type="fig"}) raises the possibility that binding of GE to RNAP may affect binding of Rif to RNAP. As a first step to assess interactions between GE and Rif, we performed fluorescence-detected binding experiments ([@bib20]) monitoring RNAP-Rif interaction in the absence and presence of GE.

The results in [Figure 6A--C](#fig6){ref-type="fig"} show that GE inhibits the binding of Rif to RNAP. GE decreases k~on~ for Rif ∼20-fold, increases k~off~ for Rif ∼fourfold, and increases the equilibrium dissociation constant (K~d~) for Rif ∼80-fold ([Figure 6C](#fig6){ref-type="fig"}). The equilibrium dissociation constant for inhibition of RNAP-Rif interaction by GE (K~i~) is 6 nM, which is comparable to the IC50 for inhibition of RNAP by GE ([Figure 6A](#fig6){ref-type="fig"}; [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}; [Supplementary file 1B](#SD1-data){ref-type="supplementary-material"}). GE^R^ RNAP derivatives do not exhibit inhibition of RNAP-Rif interaction by GE, indicating that the inhibition requires specific interactions of GE with the GE target ([Figure 6B](#fig6){ref-type="fig"}).10.7554/eLife.02450.017Figure 6.Relationship between GE and Rif: simultaneous binding.(**A**) Partial-competitive binding of GE and Rif: association kinetics for Rif in presence of 0--2000 nM GE. (**B**) Partial-competitive binding of GE and Rif: association kinetics for Rif in presence of 2000 nM GE, using wild-type RNAP (red) and GE-resistant RNAP derivatives \[Asp565\]β-RNAP (black) and \[Lys684\]β-RNAP (blue). (**C**) Partial-competitive binding of GE and Rif: k~on~, k~off~, and K~d~ for Rif in absence of GE and in presence of saturating GE (160 nM or 2000 nM; ∼30 × K~i~ or ∼300 × K~i~). (**D**) Superimposition of crystal structures of RP~o~-GE and RNAP-Rif: inferred simultaneous binding. Blue mesh, blue sticks, gray ribbon, and violet sphere: mF~o~-DF~c~ omit map for GE, atomic model for GE, RNAP, and Mg^2+^(I) from RP~o~-GE ([Figure 4](#fig4){ref-type="fig"}). Yellow sticks: Rif from RNAP-Rif (PDB: 1YNN). Green surfaces, GE target residues at which substitutions confer GE-resistance; red surfaces, residues at which substitutions confer Rif-resistance. (**E**) Crystal structure of RP~o~-GE plus Rif: crystallographic data and refinement statistics. (**F**) Crystal structure of RP~o~-GE plus Rif: electron density and model. Yellow mesh, patchy electron density potentially attributable to Rif (mF~o~-DF~c~ omit map; contoured at 2.7σ). Other colors as in **D**. (**G**) Crystal structure of RP~o~-GE-RifSV: crystallographic data and refinement statistics. (**H**) Crystal structure of RP~o~-GE-RifSV: electron density and model. Yellow mesh, mF~o~-F~c~ omit map for RifSV (contoured at 2.7σ); yellow sticks, RifSV. Other colors as in **D**. See [Figure 6---figure supplements 1, 2](#fig6s1 fig6s2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.02450.017](10.7554/eLife.02450.017)10.7554/eLife.02450.018Figure 6---figure supplement 1.Relationship between GE and Rif: effects of GE on RNAP-Rif interaction.Left panel, association kinetics: I~∞~ for RNAP-Rif interaction in the presence of 0, 2.5, 10, 40, 160, or 2000 nM GE. Center panel, association kinetics: k~obs~ for RNAP-Rif interaction in the presence of 0 or 2000 nM GE. Right panel, dissociation kinetics: I for RNAP-Rif interaction in the presence of 0 or 2000 nM GE.**DOI:** [http://dx.doi.org/10.7554/eLife.02450.018](10.7554/eLife.02450.018)10.7554/eLife.02450.019Figure 6---figure supplement 2.Relationship between GE and Rif: superimposition of crystal structures of RP~o~-GE and RP~o~-GE-RifSV showing differences in conformations of GE dmaDap residue.Blue sticks, yellow sticks, and blue numbers: GE, RifSV, and distances between GE dmaDap sidechain carbonyl carbon and RifSV C3 and O^4^ atoms, in RP~o~-GE-RifSV. Gray sticks and gray numbers: GE in RP~o~-GE and corresponding distances calculated for the GE conformation in RP~o~-GE.**DOI:** [http://dx.doi.org/10.7554/eLife.02450.019](10.7554/eLife.02450.019)

However, the results in [Figure 6A--C](#fig6){ref-type="fig"} also show that GE does not preclude the binding of Rif to RNAP. Thus, even at saturating concentrations of GE, RNAP-Rif interaction still occurs ([Figure 6A](#fig6){ref-type="fig"}) and still exhibits a submicromolar K~d~ (K~d~ = 30 nM; [Figure 6C](#fig6){ref-type="fig"}).

The results quantitatively fit a model of partial competitive binding---i.e., a model in which X inhibits the binding of Y, but in which X and Y can bind simultaneously at sufficient concentrations; [@bib65]. We infer that GE inhibits the binding of Rif to RNAP, but that GE and Rif can bind simultaneously to RNAP at sufficient concentrations. The observation that GE inhibits the binding of Rif is consistent with the fact that the GE target is adjacent to the Rif target ([Figure 2D](#fig2){ref-type="fig"}), enabling steric clash between GE bound to the GE target and Rif bound to the Rif target. The observation that GE does not preclude the binding of Rif is consistent with the observation that the GE target does not overlap with the Rif target ([Figure 2D--F](#fig2){ref-type="fig"}).

### Structural modelling of simultaneous binding of GE and a rifamycin {#s2-6-2}

As a next step to assess interactions between GE and Rif, we constructed a structural model of GE bound to the GE target and Rif bound to the Rif target. To construct the model, we superimposed the crystal structure of RP~o~-GE ([Figure 4](#fig4){ref-type="fig"}) on a crystal structure of RNAP-Rif ([@bib7]). The structural model predicts that GE bound to the GE target is located immediately adjacent to Rif bound to the Rif target ([Figure 6D](#fig6){ref-type="fig"}). The structural model further predicts that there is steric clash between GE bound to the GE target and Rif bound to the Rif target, but that clash is limited to the dmaDap sidechain of GE and the C3 atom and sidechain of Rif (cyan in [Figure 6D](#fig6){ref-type="fig"}). The predicted adjacent binding and steric clash are consistent with the observation that GE and Rif compete for binding ([Figure 6A--C](#fig6){ref-type="fig"}). The predicted limitation of the steric clash to a single moiety of GE and a single moiety of Rif is consistent with the observation that GE and Rif can bind simultaneously to RNAP at sufficient concentrations ([Figure 6A--C](#fig6){ref-type="fig"}).

### Crystal structures defining simultaneous binding of GE and a rifamycin {#s2-6-3}

As a next step to assess interactions between GE and rifamycins, we sought to determine crystal structures of RP~o~ bound simultaneously to GE and a rifamycin. In a first effort, we soaked crystals of RP~o~ with GE and Rif ([Figure 6E,F](#fig6){ref-type="fig"}). The resulting electron density maps showed unambiguous electron density for GE in the GE target, but only limited density in the Rif target ([Figure 6F](#fig6){ref-type="fig"}). In a second effort, noting that steric clash may be limited to the dmaDap sidechain of GE and the C3 atom and sidechain of Rif ([Figure 6D](#fig6){ref-type="fig"}), we soaked crystals of RP~o~ with GE and rifamycin SV (RifSV), a Rif analog that lacks the C3 sidechain and that retains high RNAP-inhibitory and antibacterial potency ([Figure 6G--H](#fig6){ref-type="fig"}; [@bib66]). In this case, the resulting electron density maps showed unambiguous electron density for GE in the GE target and for RifSV in the Rif target ([Figure 6H](#fig6){ref-type="fig"}). Occupancy levels for both GE and RifSV were 1, indicating that GE and RifSV were bound simultaneously to RNAP in the crystal. The inability to obtain a structure with simultaneously bound ligands upon crystal soaking with GE and Rif, but ability to obtain a structure with simultaneously bound ligands upon crystal soaking with GE and RifSV, highlights the contribution of the rifamycin C3 region to steric clash between GE and rifamycins.

The conformation of the GE dmaDap residue differs in RP~o~-GE and RP~o~-GE-RifSV ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). The GE dmaDap sidechain in RP~o~-GE-RifSV is rotated by ∼110°, in a direction that increases the distance between the dmaDap sidechain carbonyl carbon and the RifSV C3 atom from 3.7 Å to 8.6 Å and thereby alleviates steric clash. This observation highlights the contribution of the GE dmaDap residue to steric clash between GE and rifamycins.

Bipartite inhibitors: GE-rifamycin and GE-sorangicin {#s2-7}
----------------------------------------------------

### Structural modelling of GE-rifamycin and GE-sorangicin bipartite inhibitors {#s2-7-1}

The crystal structure of RP~o~-GE-RifSV immediately suggests the possibility of constructing a bipartite compound comprising GE, linked through its dmaDap residue, to a rifamycin, linked through its C3 or O^4^ atom ([Figure 7A](#fig7){ref-type="fig"}). Fortuitously, the GE dmaDap residue is one of three GE residues that have chemical reactivity that can be, and has been, exploited for derivatization by semi-synthesis (sole α,β-unsaturated amide moiety in GE; enables site-selective hydrolysis, ozonolysis, and 1,4-addition; [@bib42]; YWE and RHE, unpublished), and the rifamycin C3 and O^4^ atoms have chemical reactivities that can be, and extensively have been, exploited for derivatization of rifamycins by semi-synthesis ([@bib66]). Still more fortuitously, the GE dmaDap residue and the rifamycin C3 and O^4^ atoms are positions that can be modified without loss of activity ([@bib66]; [@bib42]). Accordingly, synthesis of such a bipartite compound not only is possible, but also is tractable. Such a bipartite compound is expected to be able to bind simultaneously to the GE target (through the GE moiety) and the Rif target (through the rifamycin moiety). Accordingly, such a compound is expected to have exceptionally high binding affinity, exceptionally high RNAP-inhibitory potency, and an ability to overcome resistance arising from substitutions in one of the GE target and the Rif target.10.7554/eLife.02450.020Figure 7.Bipartite inhibitors: GE-rifamycin and GE-sorangicin.(**A**) Proposed bipartite inhibitor having GE dmaDap sidechain linked to RifSV C3 or O^4^ atom. Crystal structure of RP~o~-GE-RifSV. Black line, linker. Other colors as in [Figure 6H](#fig6){ref-type="fig"}. (**B**) Proposed bipartite inhibitor having GE dmaDap sidechain linked to Sor sidechain carboxyl. Superimposition of crystal structures of RPo-GE and RNAP-Sor (PDB: 1YNJ). Cyan, Sor; red, residues at which substitutions confer Sor-resistance. Other colors as in **A**. (**C**) Synthesis of bipartite inhibitor having GE dmaDap sidechain linked to RifSV C3 atom (RifaGE-3). (**D**) Inhibition of GE-resistant RNAP (\[Asp565\]β-RNAP) by RifaGE-3. (**E**) Inhibition of Rif-resistant RNAP (\[Asn516\]β-RNAP) by RifaGE-3.**DOI:** [http://dx.doi.org/10.7554/eLife.02450.020](10.7554/eLife.02450.020)

Sor, a compound not structurally-related to rifamycins, functions by binding to the Rif binding site ([@bib7]; [@bib27]). Structural modelling of RP~o~ having GE bound to the GE target and Sor bound to the Rif binding site ([Figure 7B](#fig7){ref-type="fig"}), indicates that GE and Sor, like GE and a rifamycin, may be able to bind simultaneously to RNAP, and may be able to be linked to yield a bipartite inhibitor with exceptionally high binding affinity, exceptionally high RNAP-inhibitory potency, and an ability to overcome resistance arising from substitutions in one of the GE target and the Sor target. Fortuitously, the part of Sor that is predicted to be closest to, and potentially linkable, to GE is the Sor carboxyl moiety ([Figure 7B](#fig7){ref-type="fig"}), which has chemical reactivity that can be, and has been, exploited for derivatization of Sor by semi-synthesis, and which can be modified without loss of RNAP-inhibitory activity and antibacterial activity ([@bib29]).

### Synthesis and evaluation of a GE-rifamycin bipartite inhibitor {#s2-7-2}

We have synthesized and evaluated a bipartite inhibitor comprising a GE derivative and RifSV, covalently connected through the GE-derivative dmaDap sidechain, the RifSV C3 atom, and a one-atom linker ('RifaGE-3'; compound 3 of [Figure 7C](#fig7){ref-type="fig"}). To prepare the bipartite inhibitor, we employed a three-step procedure involving: (a) site-selective introduction of an amino group into the GE dmaDap sidechain through 1,4-addition (with concomitant heat/acid-catalyzed decarboxylation of the GE Ama sidechain), (b) reaction with 3-bromo-rifamycin S, and (c) reduction with sodium ascorbate ([Figure 7C](#fig7){ref-type="fig"}). The resulting bipartite inhibitor inhibits wild-type RNAP with an IC50 at the limit of detection of the assay (IC50 ≤40 nM), inhibits GE^R^ RNAP \>2500-fold more potently than GE ([Figure 7D](#fig7){ref-type="fig"}), and inhibits Rif^R^ RNAP 50-fold more potently than RifSV ([Figure 7E](#fig7){ref-type="fig"}). The biochemical, microbiological, and structural characterization of the bipartite inhibitor, as well as the optimization of linkage sites, linker lengths, and synthetic methods for preparation of bipartite inhibitors, will be reported separately. Nevertheless, the results in [Figure 7C--E](#fig7){ref-type="fig"} provide proof-of-concept for the synthesis, the high potency against wild-type RNAP, and the ability to overcome resistance of a GE-rifamycin bipartite inhibitor.

Discussion {#s3}
==========

Our results establish GE inhibits RNAP through a novel mechanism and a novel target. Our results show that GE inhibits the first nucleotide-addition step in transcription initiation ([Figure 1](#fig1){ref-type="fig"}), show that GE functions through a binding site that overlaps the RNAP active-center i and i+1 sites ([Figure 2](#fig2){ref-type="fig"}), define the structural basis of RNAP-GE interaction and RP~o~-GE interaction ([Figures 3,4](#fig3 fig4){ref-type="fig"}), and show that GE prevents binding of initiating NTPs to the RNAP i and i+1 sites ([Figure 5](#fig5){ref-type="fig"}).

Our results further establish that the binding site on RNAP for GE is adjacent to, but does not substantially overlap, the binding site on RNAP for the rifamycin antibacterial drugs ([Figure 2D--F](#fig2){ref-type="fig"}), show that GE and a rifamycin can bind simultaneously to their adjacent binding sites in RNAP ([Figure 6](#fig6){ref-type="fig"}), and show that GE and a rifamycin can be covalently linked, through the GE dmaDap sidechain and the rifamycin C3-O^4^ region, to yield a bipartite RNAP inhibitor that binds to both the GE target and the rifamycin target ([Figure 7](#fig7){ref-type="fig"}).

Three features of the GE target, identified in this work, indicate that the GE target is an unusually attractive target---a 'privileged target'---for antibacterial drug discovery involving RNAP. First, since most residues of the GE binding site are functionally critical residues of the RNAP active center that cannot be substituted without loss of RNAP activity, the target-based resistance spectra of an antibacterial compound that functions through the GE binding site will be small (∼1/10 the size of the target-based resistance spectrum of Rif; ∼1/10 to ∼1/5 the size of the target-based resistance spectra of RNAP inhibitors; [Figure 2D](#fig2){ref-type="fig"}; [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). Second, since the GE binding site is different from the rifamycin binding site, an antibacterial compound that functions through the GE binding site will not exhibit target-based cross-resistance with rifamycins ([Figure 2E,F](#fig2){ref-type="fig"}; [Supplementary file 2D,E](#SD2-data){ref-type="supplementary-material"}). Third, since the GE binding site is adjacent to, but does not substantially overlap, the rifamycin binding site ([Figures 2D and 6](#fig2 fig6){ref-type="fig"}), an antibacterial compound that functions through the GE binding site can be linked to a rifamycin or a sorangicin to construct a bipartite, bivalent inhibitor that binds to both the GE target and the rifamycin target and, therefore, that is exceptionally potent and exceptionally refractory to target-based resistance ([Figure 7](#fig7){ref-type="fig"}).

Materials and methods {#s4}
=====================

RNAP inhibitors {#s4-1}
---------------

GE23077 (GE) was prepared from cultures of *Actinomadura* sp. DSMZ 13491 as in [@bib10]. Sorangicin (Sor) was prepared from cultures of *Sorangium cellulosum* strain So cel2 as in [@bib28]. Lipiarmycin (Lpm) was prepared from cultures of *Actinoplanes deccanensis* as in [@bib12]. (±)E,E-myxopyronin B (Myx) was synthesized as in [@bib16]. Rifampin (Rif), rifamycin SV (RifSV), streptolydigin (Stl), and CBR703 were purchased from Sigma--Aldrich (St. Louis, MO), Sigma--Aldrich, Sourcon-Padena (Tübingen, Germany), and Maybridge (Tintagel, UK), respectively.

Plasmids {#s4-2}
--------

Plasmid pRL706 encodes C-terminally hexahistidine-tagged *E. coli* RNAP β subunit under control of the *trc* promoter ([@bib62]). Plasmid pRL663 encodes C-terminally hexahistidine-tagged *E. coli* RNAP β′ subunit under control of the *tac* promoter ([@bib78]). Plasmid pKD46 carries a temperature-sensitive replication origin, confers ampicillin-resistance, and encodes λ Exo, Beta, and Gam, under control of the *P*~*araB*~ promoter ([@bib13]). Plasmid pAKE604 confers kanamycin-resistance and sucrose-sensitivity ([@bib17]).

*E. coli* RNAP holoenzyme {#s4-3}
-------------------------

*E. coli* RNAP, \[Asn516\]β-RNAP, \[Asp565\]β-RNAP, and \[Lys684\]β-RNAP core and holoenzyme were prepared from *E. coli* strain XE54 ([@bib73]) transformed with pRL706, pRL706-516N, pRL706-565D, and pRL706-684K, respectively, using procedures essentially as in [@bib51]. *E. coli* RNAP holoenzyme derivatives site-specifically labelled with fluorescein at σ^70^ residue 517 (\[F^517^\]σ^70^-RNAP holoenzyme derivatives) were prepared as in [@bib33].

*T. thermophilus* RNAP holoenzyme {#s4-4}
---------------------------------

*T. thermophilus* RNAP holoenzyme was prepared as in [@bib84].

RNAP-inhibitory activity {#s4-5}
------------------------

Fluorescence-detected RNAP-inhibition assays were performed by a modification of the procedure of [@bib34]. Reaction mixtures contained (20 μl): 0--100 μM test compound, bacterial RNAP holoenzyme (75 nM *E. coli* RNAP holoenzyme or *E. coli* RNAP holoenzyme derivative, 75 nM *Staphylococcus aureus* RNAP core enzyme and 300 nM *S. aureus* σ^A^ \[prepared as in [@bib70]\], 75 nM *Mycobacterium tuberculosis* RNAP core enzyme and 300 nM *M. tuberculosis* σ^A^ \[prepared as in [@bib70]\], or 75 nM *T. thermophilus* RNAP holoenzyme), 20 nM DNA fragment containing the bacteriophage T4 N25 promoter (positions −72 to +367; prepared by PCR from plasmid pARTaqN25-340-tR2 \[[@bib39]\]), 100 μM ATP, 100 μM GTP, 100 μM UTP, and 100 μM CTP, in TB (50 mM Tris--HCl, pH 8.0, 100 mM KCl, 10 mM MgCl~2~, 1 mM DTT, 10 μg/ml bovine serum albumin, 5% methanol, and 5.5% glycerol). Reaction components other than DNA and NTPs were pre-incubated 10 min at 37°C. Reactions were carried out by addition of DNA and incubation 15 min at 37°C, followed by addition of NTPs and incubation 60 min at 37°C. DNA was removed by addition of 1 μl 5 mM CaCl~2~ and 2 U DNase I (Ambion, Grand Island, NY), followed by incubation 90 min at 37°C. RNA was quantified by addition of 100 μl Quant-iT RiboGreen RNA Reagent (Life Technologies, Grand Island, NY; 1:500 dilution in 10 mM Tris--HCl, pH 8.0, 1 mM EDTA), followed by incubation 10 min at 22°C, followed by measurement of fluorescence intensity (excitation wavelength = 485 nm and emission wavelength = 535 nm; GENios Pro microplate reader \[Tecan, Männedorf, Switzerland\]).

Radiochemical assays with human RNAP I/II/III were performed essentially as in [@bib59]. Reaction mixtures contained (20 µl): 0--100 µM GE, 8 U HeLaScribe Nuclear Extract (Promega, Madison, WI), 1 µg human placental DNA (Sigma--Aldrich), 400 μM ATP, 400 μM \[α^32^P\]UTP (0.11 Bq/fmol), 400 μM CTP, 400 μM GTP, 50 mM Tris--HCl, pH 8.0, 7 mM HEPES-NaOH, 70 mM (NH~4~)~2~SO~4~, 50 mM KCl, 12 mM MgCl~2~, 5 mM DTT, 0.1 mM EDTA, 0.08 mM phenylmethylsulfonyl fluoride, and 16% glycerol. Reaction components other than DNA and NTPs were pre-incubated 10 min at 30°C, DNA was added and reaction mixtures were incubated 15 min at 30°C, NTPs were added and reaction mixtures were incubated 60 min at 30°C. Reaction mixtures were spotted on DE81 filter discs (Whatman, Kent, UK; pre-wetted with water) and incubated 1 min at room temperature. Filters were washed with 3 × 3 ml Na~2~HPO~4~, 2 × 3 ml water, and 3 ml ethanol, using a filter manifold (Hoefer, Holliston, MA). Filters were placed in scintillation vials containing 10 ml Scintiverse BD Cocktail (Thermo Fisher, Waltham, MA), and radioactivity was quantified by scintillation counting (LS6500; Beckman--Coulter, Brea, CA).

Half-maximal inhibitory concentrations (IC50s) were calculated by non-linear regression in SigmaPlot (SPSS, Chicago, IL).

Antibacterial activity {#s4-6}
----------------------

Minimum inhibitory concentrations (MICs) were quantified using broth microdilution assays ([@bib11]), using a starting cell density of 3 × 10^4^ cfu/ml, LB broth ([@bib57]), and an air atmosphere for *E. coli* D21f2tolC (*tolC:*Tn*10 rfa lac28 proA23 trp30 his51 rpsL173 ampC tsx81*; strain with cell-envelope defects resulting in increased susceptibility to hydrophobic agents, including GE; Fralick and Burns-Keliher, 1994; unpublished data), and using a starting cell density of 3 × 10^4^ cfu/ml, Bacto Todd Hewitt broth (TH broth; BD Biosciences, San Jose, CA), and a 7% CO~2~/6% O~2~/4% H~2~/83% N~2~ atmosphere for *S. pyogenes* and *M. catarrhalis*.

GE-resistant mutants: isolation and sequencing {#s4-7}
----------------------------------------------

Saturation mutagenesis of *rpoB* plasmid pRL706 and *rpoC* plasmid pRL663 was performed by use of PCR amplification with 'doped' oligodeoxyribonucleotide primers (methods as in [@bib46]). 'Doped' oligodeoxyribonucleotide primers corresponding to codons 136-143, 504-511, 512-522, 523-534, 535-541, 542-549, 563-573, 677-690, 758-763, 813-814, 829-835, 1054-1060, 1064-1074, 1102-1108, and 1233-1242 of the *rpoB* gene of plasmid pRL706, and codons 347-355, 425-429, 456-465, 779-792, and 934-943 of the *rpoC* gene of plasmid pRL663, were synthesized on an Applied Biosystems 392/394 automated DNA/RNA synthesizer (Foster City, CA) using solid-phase β-cyanoethylphosphoramidite chemistry (sequences in [Supplementary file 2A](#SD2-data){ref-type="supplementary-material"}). The level of 'doping' (nucleotide misincorporation) was selected to yield an average of 0.4--1 substitution(s) per molecule of oligodeoxyribonucleotide primer (equations in [@bib26], [@bib25]). Thus, the nucleotides corresponding to codons 758-763 and 813-814 of *rpoB*, and codons 425-429 of *rpoC* were synthesized using phosphoramidite reservoirs containing 92% of the correct phosphoramidite and 8% of a 1:1:1:1 mix of dA, dC, dG, and dT phosphoramidites (i.e., 94% total correct phosphoramidite and 6% total incorrect phosphoramidite). The nucleotides corresponding to codons 136-143, 504-511, 512-522, 523-534, 535-541, 542-549, 563-573, 677-690, 829-835, 1054-1060, 1064-1074, 1102-1108, and 1233-1242 of *rpoB*, and codons 347-355, 456-465, 779-792, and 934-943 of *rpoC* were synthesized using phosphoramidite reservoirs containing 98% of the correct phosphoramidite and 2% of a 1:1:1:1 mix of dA, dC, dG, and dT phosphoramidites, (i.e., 98.5% total correct phosphoramidite and 1.5% total incorrect phosphoramidite.) All other nucleotides were synthesized using phosphoramidite reservoirs containing 100% of the correct phosphoramidite. Mutagenesis reactions were performed using the QuikChange XL Site-Directed Mutagenesis Kit (Agilent/Stratagene, La Jolla, CA) with a "doped" oligodeoxyribonucleotide primer, a complementary oligodeoxyribonucleotide primer, and pRL706 or pRL663 as template (primers at 75-150 nM; all other components at concentrations as specified by the manufacturer). Mutagenized plasmid DNA was introduced by transformation into *E. coli* XL1-Blue (Agilent/Stratagene). Transformants (10^3^-10^4^ cells) were applied to LB-agar plates ([@bib57]) containing 200 μg/ml ampicillin, plates were incubated 16 hr at 37°C, and plasmid DNA was prepared from the pooled resulting colonies. The resulting passaged mutagenized plasmid libraries for the 15 "doped" oligonucleotide primers targeting *rpoB* were pooled on an equimolar basis, and the resulting passaged mutagenized plasmid libraries for the five "doped" oligonucleotide primers targeting *rpoC* were pooled on an equimolar basis. Pooled, passaged mutagenized plasmid libraries for each gene were introduced by transformation into *E. coli* D21f2tolC. Transformants (∼10^3^ cells) were applied to LB-agar plates containing 200-500 μg/ml GE, 200 μg/ml ampicillin, and 1 mM IPTG; and plates were incubated 24-48 hr at 37°C. GE-resistant mutants were identified by the ability to form colonies on this medium, were confirmed by re-streaking on the same medium, were further confirmed by quantifying resistance levels in liquid cultures and accepting only isolates with \>2-fold resistance (procedures as described below), and were demonstrated to contain plasmid-linked GE-resistant mutations by preparing plasmid DNA, transforming *E. coli* D21f2tolC with plasmid DNA, and plating transformants on the same medium. For each confirmed mutant, nucleotide sequences of *rpoB* and *rpoC* were determined by Sanger sequencing (eight primers per gene).

GE-resistant mutants: complementation assays {#s4-8}
--------------------------------------------

Temperature-sensitive *E. coli* strain RL585 \[*rpoB*^*am*^*cI supD*^*ts*^*43,74* Δ*(recA-srl)306 lacZ*^*am*^*2110 galEK*^*am*^ *leu*^*am*^ *trp*^*am*^ *sueA rpsL tsx srl301*::Tn*10-84*; [@bib35]\] was transformed with pRL706 or a pRL706 derivative, transformants (10^3^-10^4^ cells) were applied to LB-agar plates containing 200 μg/ml ampicillin, 1 mM IPTG, and 10 μg/ml tetracycline, plates were incubated 22 hr at 43°C, and bacterial growth was scored.

GE-resistant mutants: transfer to chromosome {#s4-9}
--------------------------------------------

GE-resistant and Rif-resistant mutations were transferred from pRL706 derivatives to the chromosome of *E. coli* D21f2tolC by λ-Red-mediated recombineering (procedures analogous to those in [@bib13] and [@bib60]; but using chemical transformation rather than electroporation). DNA fragments (143 bp or 306 bp) containing *rpoB* segments with GE-resistant or Rif-resistant mutations were prepared by PCR amplification using pRL706 derivatives carrying GE-resistant and Rif-resistant mutations as templates and 5'-CAGGTGGTATCCGTCGGTGCGTCCCTG-3' and 5'-CGTTCCATACCAGTACCAACCAGCGGC-3' (for GE-resistant mutations) or 5′-GGATATGATCAACGCCAAGCCGATTTCCGCAGC-3′ and 5′-CGATACGGAGTCTCAAGGAAGCCGTATTCG-3′ (for Rif-resistant mutations) as primers. DNA fragments were purified by isolation by electrophoresis on 0.8% agarose (procedures as in [@bib57]) and extracted from gel slices using a Gel/PCR DNA Fragments Extraction Kit (IBI Scientific, Peosta, IA; procedures as specified by the manufacturer).

DNA fragments and co-selection/counter-selection plasmid pAKE604 (10 ng and 100 ng; for GE-resistant mutations) or DNA fragments only (30 ng; for Rif-resistant mutations) were introduced by transformation into chemically competent cells of *E. coli* D21f2tolC pKD46 (prepared by culturing *E. coli* D21f2tolC pKD46 in LB broth containing 200 μg/ml ampicillin and 1 mM arabinose at 30°C until OD = 0.6, pelleting cells, re-suspending cells in 85% LB, 10% PEG 3350, 5% DMSO, and 50 mM MgCl~2~, and flash freezing in dry-ice/ethanol), and transformants were cultured 3.5 hr at 37°C with shaking, applied to LB-agar plates containing 500 μg/ml GE and 40 μg/ml kanamycin (for GE-resistant mutations) or 1--2 μg/ml Rif (for Rif-resistant mutations), and incubated 24-30 hr at 37°C. Isolates containing chromosomal GE-resistant or Rif-resistant mutations were identified by the ability to form colonies on media containing GE or Rif, were confirmed by re-streaking on the same media, and were verified to have lost temperature-sensitive plasmid pKD46 by re-streaking on LB-agar plates containing 0 or 200 μg/ml ampicillin. For GE-resistant isolates, segregants lacking *sacB* plasmid pAKE604 were identified and verified by plating on LB agar containing 5% sucrose. Isolates were demonstrated to contain the expected mutations by PCR amplification and nucleotide sequencing of *rpoB*.

GE-resistant mutants: determination of resistance levels {#s4-10}
--------------------------------------------------------

Resistance levels of GE-resistant mutants were quantified by performing broth microdilution assays. Single colonies were inoculated into 5 ml LB broth containing 200 μg/ml ampicillin, and 1 mM IPTG (for *E. coli* plasmid-borne mutants and controls), 5 ml LB broth (for *E. coli* chromosomal mutants and controls), or 5 ml TH broth (for *S. pyogenes* mutants and controls) and incubated at 37°C with shaking in air (for *E. coli*) or in 7% CO~2~/6% O~2~/4% H~2~/83% N~2~ (for *S. pyogenes*) until OD~600~ = 0.4--0.8. Diluted aliquots (∼4 × 10^5^ cells in 50 μl of the same medium) were dispensed into wells of a 96-well plate containing 50 μl of the same medium or 50 μl of a twofold dilution series of GE in the same medium (final concentrations = 0 and 8--8000 μg/ml), and were incubated 16 hr at 37°C with shaking under the same conditions. The MIC was defined as the lowest tested concentration of GE that inhibited bacterial growth by ≥90%.

GE-resistant mutants: determination of cross-resistance levels {#s4-11}
--------------------------------------------------------------

Cross-resistance levels were determined analogously to resistance levels. Liquid cultures were prepared as described above for determination of resistance levels. Diluted aliquots of cultures (∼2 × 10^5^ cells in 97 μl growth medium) were dispensed into wells of a 96-well plate, were supplemented with 3 μl methanol or 3 μl of a twofold dilution series of Rif, Sor, Stl, CBR703, Myx, or Lpm in methanol (final concentrations = 0 and 0.012--50 μg/ml), and were incubated 16 hr at 37°C with shaking.

Formation of RNAP-promoter open complex {#s4-12}
---------------------------------------

Reaction mixtures contained (20 μl): test compound (0 or 0.5 μM GE, or 2.2 μM Rif), 40 nM *E. coli* RNAP holoenzyme, 10 nM DNA fragment containing positions −42 to +426 of the *lacUV5(ICAP)* promoter ([@bib50]), and 100 μg/ml heparin, in TB. Reaction components other than DNA and heparin were pre-incubated 10 min at 37°C; DNA was added and reaction mixtures were incubated 15 min at 37°C; heparin was added and reactions were incubated 2 min at 37°C to disrupt non-specific RNAP-promoter complexes and RNAP-promoter closed complexes ([@bib8]). Products were applied to 5% TBE polyacrylamide slab gels (Bio-Rad, Hercules, CA), gels were electrophoresed in TBE (90 mM Tris-borate, pH 8.0, and 2 mM EDTA), and gels were stained with SYBR Gold Nucleic Acid Gel Stain (Life Technologies).

Nucleotide addition in transcription initiation: primer-dependent initiation {#s4-13}
----------------------------------------------------------------------------

Reaction mixtures contained (20 μl): test compound (0 or 0.5 μM GE, or 2.2 μM Rif), 5 nM *E. coli* RNAP holoenzyme \[Epicentre\], 2.5 nM DNA fragment containing positions −49 to +30 of the *lacCONS* promoter ([@bib47]), 25 μg/ml heparin, 500 μM ApA, and 25 μM \[α^32^P\]UTP (0.9 Bq/fmol) in TB. Reaction components other than DNA, heparin, ApA, and \[α-^32^P\]UTP were pre-incubated 10 min at 37°C; DNA was added and reaction mixtures were incubated 15 min at 37°C; heparin was added and reaction mixtures were incubated 2 min at 37°C; ApA and \[α^32^P\]UTP were added and reaction mixtures were incubated 10 min at 37°C. Reactions were terminated by adding 10 μl 80% formamide, 10 mM EDTA, 0.04% bromophenol blue, 0.04% xylene cyanol, and 0.08% amaranth red. Products were heated 5 min at 90°C, cooled 5 min on ice, applied to 16% polyacrylamide (19:1 acrylamide:bisacrylamide, 7 M urea) slab gels, electrophoresed in TBE, and analyzed by storage-phosphor scanning (Typhoon; GE Healthcare, Piscataway, NJ). Identities of tri- and tetranucleotide abortive products from transcription initiation at lacUV5 were defined as in [@bib4].

Nucleotide addition in transcription initiation: de novo initiation {#s4-14}
-------------------------------------------------------------------

Reaction mixtures contained (20 μl): 0 or 0.5 μM GE, 100 nM *E. coli* RNAP holoenzyme, 20 nM DNA fragment containing positions −65 to +35 of the bacteriophage T7 A1 promoter (prepared by PCR amplification of a synthetic nontemplate-strand oligodeoxyribonucleotide), 25 μg/ml heparin, 25 μM ATP, and 25 μM \[α^32^P\]UTP (0.7 Bq/fmol) in TB. Reaction components other than DNA, heparin, and NTPs were pre-incubated 5 min at 23°C, DNA was added and reaction mixtures were incubated 15 min at 37°C, heparin and NTPs were added were added and incubated 5 min at 37°C. Reactions were terminated by adding 10 μl 80% formamide, 10 mM EDTA, 0.04% bromophenol blue, and 0.04% xylene cyanol. Products were heated 5 min at 95°C, cooled 5 min on ice, and applied to 16% polyacrylamide (19:1 acrylamide:bisacrylamide, 7 M urea) slab gels, electrophoresed in TBE, and analyzed by storage-phosphor scanning (Typhoon; GE Healthcare).

Nucleotide addition in transcription elongation: halted elongation complexes {#s4-15}
----------------------------------------------------------------------------

Halted transcription elongation complexes (halted at position +29) were prepared essentially as in [@bib54a]. Reaction mixtures (18 μl) contained: 40 nM *E. coli* RNAP holoenzyme, 10 nM DNA fragment N25-100-tR2 ([@bib54a]), 100 μg/ml heparin, 5 μM ATP, 5 μM GTP, and 5 μM \[α^32^P\]UTP (4 Bq/fmol) in TB. Reaction components except heparin and NTPs were pre-incubated 10 min at 37°C; heparin was added and reaction mixtures were incubated 2 min at 37°C; NTPs were added and reaction mixtures were incubated 5 min at 37°C. The resulting halted transcription elongation complexes were exposed to test compounds by addition of 1 μl 10 μM GE or 1 μl 44 μM Rif, incubated 5 min at 37°C, and were re-started by addition of 1 μl 1 mM CTP and incubation 5 min at 37°C. Reactions were terminated by adding 10 μl 80% formamide, 10 mM EDTA, 0.04% bromophenol blue, 0.04% xylene cyanol, and 0.08% amaranth red. Products were heated 5 min at 90°C, cooled 5 min on ice, applied to 16% polyacrylamide (19:1 acrylamide:bisacrylamide, 7 M urea) slab gels, electrophoresed in TBE, and analyzed by storage-phosphor scanning (Typhoon; GE Healthcare).

Nucleotide addition in transcription elongation: reconstituted elongation complexes {#s4-16}
-----------------------------------------------------------------------------------

Nucleic-acid scaffolds for assays were prepared as follows: nontemplate-strand oligodeoxyribonucleotide (5′-TCGCCAGACAGGG-3′; 1 μM), template-strand oligodeoxyribonucleotide (5′-CCCTGTCTGGCGATGGCGCGCCG-3′; 1 μM), and ^32^P-5′-end-labelled oligoribonuceotide (5′-^32^P-CGGCGCGCC-3′; 1 μM; 200 Bq/fmol) in 25 μl 5 mM Tris--HCl, pH 7.7, 200 mM NaCl, and 10 mM MgCl~2~, were heated 5 min at 95°C and cooled to 4°C in 2°C steps with 1 min per step using a thermal cycler (Applied Biosystems) and then were stored at −20°C.

Reaction mixtures for assays contained (15 μl): 0 or 0.5 μM GE or 0 or 2.2 μM Rif, 40 nM wild-type *E. coli* RNAP core enzyme (Epicentre, Madison, WI), 10 nM ^32^P-labelled nucleic-acid scaffold (200 Bq/fmol), and 20 μM ATP in TB. Reaction components except inhibitors and ATP were pre-incubated 5 min at 37°C, GE or Rif was added and reaction mixtures were incubated 5 min at 37°C, and ATP was added and reaction mixtures were incubated 2 min at 37°C. Reactions were terminated by adding 15 μl 80% formamide, 10 mM EDTA, 0.04% bromophenol blue, and 0.04% xylene cyanol, and heating 2 min at 95°C. Products were applied to 20% polyacrylamide (19:1 acrylamide:bisacrylamide, 7 M urea) slab gels, electrophoresed in TBE, and analyzed by storage-phosphor scanning (Typhoon; GE Healthcare).

RNAP-Rif interaction assays {#s4-17}
---------------------------

RNAP-Rif interaction assays were performed as in [@bib20]. The assays monitored the quenching of the fluorescence emission of fluorescein incorporated into RNAP holoenzyme at σ^70^ residue 517 (serving as a fluorescence-resonance-energy-transfer donor) by the naphthyl moiety of Rif (serving as a fluorescence-resonance-energy-transfer acceptor; [@bib33]; [@bib20]). Fluorescence measurements were performed using a QuantaMaster QM1 spectrofluorometer (PTI, Edison, NJ) (excitation wavelength = 480 nm; emission wavelength = 530 nm; and excitation and emission slit widths = 5 nm).

For determination of association kinetics, 720 μl 2 nM \[F^517^\]σ^70^-RNAP holoenzyme and 0-2 μM GE in 40 mM Tris--HCl, pH 8.0, 100 mM NaCl, 10 mM MgCl~2~, 1 mM DTT, 0.02% Tween-20, and 5% glycerol was incubated 15 min at 24°C and then mixed with 30 μl 0.01--0.5 μM Rif in the same buffer at 24°C in a cuvette chamber with a mixing dead time ∼0.5 s, and fluorescence emission intensities were monitored for 30 min at 24°C. On-rates for RNAP-Rif interaction, k~on~, were calculated by fitting data to:$${\text{I} = \left( \text{I} \right.}_{0}{- \text{I}}_{\infty}{)\text{exp}\left( - \text{k} \right.}_{\text{obs}}{\left. \text{t} \right) + \text{I}}_{\infty}$$where k~obs~ is the observed association rate constant at a specified Rif concentration, I is the fluorescence emission intensity at time t, I~o~ is the fluorescence emission intensity at t = 0, and I~∞~ is the fluorescence emission intensity at t = ∞; followed by fitting the Rif-concentration-dependence of k~obs~ to:$$\text{k}_{\text{obs}}{= \text{k}}_{\text{on}}{\left\lbrack \text{Rif} \right\rbrack + \text{k}}_{\text{off}}$$where k~off~ is ≥0 but is otherwise unconstrained.

For determination of dissociation kinetics, 720 μl of 2 nM \[F^517^\]σ^70^-RNAP holoenzyme and 0.05 μM Rif in the same buffer was incubated 30 min at 24°C and then mixed with 30 μl of 0--50 μM GE and 12.5--50 μM Sor (which binds to the same site as Rif but does not quench fluorescence emission and therefore serves as a 'competitor trap' for Rif dissociation kinetics; [@bib20]) in the same buffer at 24°C in a cuvette chamber with a mixing dead time ∼0.5 s; and fluorescence emission intensities were monitored for 5--300 min at 24°C. Dissociation kinetics were found not to depend on the concentration of Sor in the concentration range used in this work (final concentrations of 0.5--2 μM), verifying that Sor in this concentration range does not compete with GE and does not actively displace Rif from RNAP. Off-rates for RNAP-Rif interaction, k~off~, were calculated as:$$\left. {\text{I} = \text{I}}_{0}{+ \left( \text{I} \right.}_{\infty}{- \text{I}}_{\text{0}}{)\left\lbrack \text{1} - \text{exp}\left( - \text{k} \right. \right.}_{\text{off}}\text{t} \right)\rbrack$$where I is the fluorescence emission intensity at time t, I~o~ is the fluorescence intensity at t = 0, and I~∞~ is the fluorescence intensity at t = ∞.

Equilibrium dissociation constants for RNAP-Rif interaction, K~d~, were calculated as k~off~/k~on~.

The equilibrium dissociation constant for RNAP-GE interaction, K~i~, was calculated from the association-kinetics data, by fitting the GE-concentration-dependence of I~∞~ to:$$\text{I}_{\infty} = {{\left( \text{I} \right._{\infty\text{,max}}\left\lbrack \text{GE} \right\rbrack)}/{\left( \text{K} \right._{\text{i}} + \left\lbrack \text{GE} \right\rbrack)}}$$

Structure determination: RNAP + GE {#s4-18}
----------------------------------

Crystallization and crystal handling were performed essentially as in [@bib75]. A crystallization stock solution was prepared by adding 1 μl *T. thermophilus* RNAP holoenzyme (10 mg/ml) in 20 mM Tris--HCl, pH 7.7, 100 mM NaCl, and 1% glycerol to 1 μl 33 mM magnesium formate containing 40 μM ZnCl~2~. The crystallization stock solution was equilibrated against a reservoir solution of 30 mM sodium citrate, pH 5.4, and 35 mM magnesium formate in a vapor-diffusion hanging-drop crystallization tray (Hampton Research, Aliso Viejo, CA) at 22°C. Hexagonal crystals formed and grew to a final size of ∼0.4 × ∼0.4 × ∼0.2 mm within 6 d.

GE was soaked into RNAP crystals by addition of 0.2 μl 10 mM GE in 60% (vol/vol) (±)-2-methyl-2,4-pentanediol (MPD; Hampton Research) to the crystallization drop and incubation 15 min at 22°C. Crystals were transferred to solutions containing 0.5 mM GE, 20 mM MES, pH 6.0, 13 mM magnesium formate, 2 mM spermine, 2 mM DTT, 5% PEG400, and 15% (vol/vol) (2R,3R)-(−)-2,3-butanediol (Sigma--Aldrich), and were flash-cooled with liquid nitrogen.

Diffraction data for RNAP-GE were collected at Cornell High Energy Synchrotron Source (CHESS) beamline F1 and were processed and scaled using iMOSFLM and SCALA ([@bib3]; [@bib19]). The structure of RNAP-GE was solved by molecular replacement with AutoMR in Phenix ([@bib45]) using a modified structure of *T. thermophilus* RNAP holoenzyme (PDB 3DXJ; [@bib46]) as the search model. Early stages of refinement of the RNAP-GE complex included rigid-body refinement of subdomains (∼15--200 residue segments) of the RNAP molecule. Cycles of rigid-body, individual-atom, and individual-B-factor refinement using Ramachandran and secondary structure restraints and optimized weights for stereochemistry and optimized atomic displacement parameters were carried out using Phenix ([@bib1]). Manual rebuilds against electron-density maps were performed using Coot ([@bib18]) and Molprobity ([@bib14]; [@bib9]). In addition, two refinement cycles were performed within Autobuster ([@bib5]). For GE backbone atoms and GE sidechain atoms with previously defined stereochemistry ([@bib40]), an initial atomic model was generated using Maestro (Schrodinger, Portland, OR) and was fit to mFo-DFc maps using Phenix ([@bib1]). For GE sidechain atoms with previously undefined stereochemistry, stereochemistry was deduced and atoms were added based on assessment of mFo-DFc maps and RNAP-GE interactions using PrimeX (Schrodinger). All GE atoms could be fitted to density except atoms of the GE dmaDap residue distal to the sidechain carbonyl moiety. Subsequent cycles of refinement and model building were performed, leading to the current crystallographic model, with a standard crystallographic residual of R~work~ = 0.21 and R~free~ = 0.24 computed using all data from 38.97 to 3.35 Å resolution. Atomic coordinates and structure factors for RNAP-GE have been deposited in the PDB with accession code 4MQ9.

Structure determination: RP~o~ + GE {#s4-19}
-----------------------------------

Crystals of *T. thermophilus* RP~o~ were prepared using the same nucleic-acid scaffold as used for analysis of RP~o~ in [@bib84], and were grown and handled essentially as in [@bib84]. Crystallization drops contained 1 μl RP~o~ in 20 mM Tris--HCl, pH 7.7, 100 mM NaCl, and 1% glycerol, and 1 μl reservoir buffer (RB; 100 mM Tris--HCl, pH 8.4, 200 mM KCl, 50 mM MgCl~2~, and 9.5% PEG4000), and were equilibrated against 400 μl RB in a vapor-diffusion hanging-drop tray. Rod-like crystals appeared in 1 d, and were used to micro-seed hanging drops using the same conditions.

GE was soaked into RP~o~ crystals by addition of 0.2 μl 20 mM GE in RB to the crystallization drop and incubation 15 min at 22°C. Crystals were transferred in stepwise fashion to successive reservoir solutions containing 1 mM GE in 0.5%, 1%, 2.5%, 5%, 10%, 14%, and 17.5% (v/v) (2R, 3R)-(−)-2,3-butanediol (20 s for first step and 2 s for each subsequent step) and were flash-cooled with liquid nitrogen.

Diffraction data were collected at CHESS beamline F1 and Brookhaven National Laboratory (BNL) beamline X29A and were processed using HKL2000 ([@bib52]). Structure factors were converted using the French-Wilson algorithm in Phenix ([@bib21]) and were subjected to anisotropy correction using the UCLA MBI Diffraction Anisotropy server ([@bib71]; <http://services.mbi.ucla.edu/anisoscale/>). The structure was solved by molecular replacement with Molrep ([@bib76]) using one RNAP molecule from the structure of *T. thermophilus* RP~o~ (PDB 4 G7H; [@bib84]) as the search model. Early-stage refinement included rigid-body refinement of the RNAP molecule, followed by rigid-body refinement of each subunit of RNAP molecule. Cycles of iterative model building with Coot ([@bib18]) and refinement with Phenix ([@bib1]) were performed. Atomic models of the DNA nontemplate strand, the DNA template strand, and GE were built into mFo-DFc omit maps, and subsequent cycles of refinement and model building were performed. The final crystallographic model of RP~o~-GE, refined to R~work~ and R~free~ of 0.21 and 0.25, has been deposited in the PDB with accession code 4OIN.

Structure determination: RP~o~ + ATP + CMPcPP {#s4-20}
---------------------------------------------

ATP (Sigma--Aldrich) and CMPcPP (Jena Biosciences, Jena, Germany) were soaked into RP~o~ crystals (prepared as described above, using the nucleic-acid scaffold used for analysis of RP~o~-GpA in [@bib84]) by addition of 0.2 μl 30 mM ATP and 30 mM CMPcPP in 55% (vol/vol) RB to the crystallization drop, and incubation 15--20 min at 22°C. Crystals were transferred into reservoir solutions containing 2 mM ATP and 2 mM CMPcPP in 17.5% (vol/vol) (2R, 3R)-(−)-2,3-butanediol and were flash-cooled with liquid nitrogen.

Diffraction data were collected at BNL beamline X25, processed and scaled using HKL2000 ([@bib52]), and subjected to anisotropic correction using the UCLA MBI Diffraction Anisotropy server ([@bib71]; <http://services.mbi.ucla.edu/anisoscale/>). The structure was solved and refined using procedures analogous to those described above for RP~o~-GE. The final crystallographic model contained RP~o~, ATP bound in the RNAP i site, and CMPcPP:Mg^2+^ bound in the RNAP i+1 site. The final crystallographic model of RP~o~-ATP-CMPcPP, refined to R~work~ and R~free~ of 0.21 and 0.26, respectively, has been deposited in the PDB with accession code 4OIO.

Structure determination: RP~o~ + GE + ATP + CMPcPP {#s4-21}
--------------------------------------------------

Crystals of RP~o~ (prepared as described above for RP~o~ + ATP + CMPcPP) first were soaked with GE (addition of 0.2 μl 20 mM GE in RB to the crystallization drop and incubation 15 min at 22°C) and then were soaked with ATP and CMPcPP (addition of 0.2 μl 30 mM ATP and 30 mM CMPcPP in 55% \[vol/vol\] RB to the crystallization drop and incubation 15 min at 22°C). Crystals then were transferred to reservoir solutions containing 1 mM GE, 2 mM ATP, and 2 mM CMPcPP in 17.5% (vol/vol) (2R, 3R)-(−)-2,3-butanediol and were flash-cooled with liquid nitrogen.

Diffraction data were collected at BNL beamline X25, and were processed, scaled, and corrected for anisotropy using HKL2000 ([@bib52]). The structure was solved and refined using procedures analogous to those described above for RP~o~-GE. The final crystallographic model contained RP~o,~ GE bound to the GE target, and ATP:Mg^2+^ bound to the RNAP E site, and did not contain ATP in the RNAP i site or CMPcPP in RNAP i+1 site. The final crystallographic model, refined to R~work~ and R~free~ of 0.21 0.25, respectively, has been deposited in the PDB with accession code 4OIP.

Structure determination: RP~o~ + GE + Rif {#s4-22}
-----------------------------------------

Crystals of RP~o~ (prepared as described above for RP~o~ + ATP + CMPcPP) first were soaked with Rif (addition of 0.1 μl 20 mM Rif in RB containing 40% \[vol/vol\] \[2R, 3R\]-(−)-2,3-butanediol to the crystallization drop and incubation 15 min at 22°C) and then were soaked with GE (addition of 0.2 μl 20 mM GE in RB to the crystallization drop and incubation 15 min at 22°C). Crystals then were transferred to reservoir solutions containing 1 mM GE and 0.4 mM Rif in 17.5% (vol/vol) (2R, 3R)-(−)-2,3-butanediol and were flash-cooled with liquid nitrogen.

Diffraction data were collected at CHESS beamline F1, and were processed and scaled using HKL2000 ([@bib52]). The structure was solved and refined using procedures analogous to those described above for RP~o~-GE. The final crystallographic model contained RP~o~ and GE bound to the GE target but did not contain Rif. The final crystallographic model, refined to R~work~ and R~free~ of 0.20 and 0.25, respectively, has been deposited in the PDB with accession code 4OIQ.

Structure determination: RP~o~ + GE + RifSV {#s4-23}
-------------------------------------------

Crystals of RPo (prepared as described above for RP~o~ + ATP + CMPcPP) first were soaked with RifSV (addition of 0.2 μl 10 mM RifSV in RB to the crystallization drop and incubation 15 min at 22°C, or transfer of the crystal to 1 μl 10 mM RifSV in RB and incubation 15 min at 22°C) and then were soaked with GE (addition of 0.2 μl 20 mM GE in RB to the drop and incubation 15 min at 22°C). Crystals then were transferred in to reservoir solutions containing 1 mM GE and 1 mM RifSV in 17.5% (vol/vol) (2R, 3R)-(−)-2,3-butanediol and were flash-cooled with liquid nitrogen.

Diffraction data were collected at BNL beamline X25, were processed and scaled using HKL2000 ([@bib52]), and were subjected to anisotropic correction using the UCLA MBI Diffraction Anisotropy server ([@bib71]; <http://services.mbi.ucla.edu/anisoscale/>). The structure was solved and refined using procedures analogous to those described above for RP~o~-GE. The final crystallographic model contained RP~o~, GE bound to the GE target, and RifSV bound to the Rif target. The final crystallographic model of RP~o~-GE-RifSV, refined to R~work~ and R~free~ of 0.21 and 0.25, respectively, has been deposited in the PDB with accession code 4OIR.

Synthesis of a GE-rifamycin bipartite inhibitor: step 1, synthesis of \[ζ^1^-amino-dmaDap; α-descarboxy-Ama\]GE (compound 1 of [Figure 7C](#fig7){ref-type="fig"}) {#s4-24}
------------------------------------------------------------------------------------------------------------------------------------------------------------------

GE (20 mg 25 μmol), ammonium acetate (60 mg; 780 μmol; Aldrich), and perchloric-acid-impregnated silica (5 mg; prepared as in [@bib67]), were mixed in 4 ml absolute ethanol in a screw-cap vial. The mixture was microwaved for 4 × 30 s (1000 W) with intervals of 1 min for re-mixing contents of the vial. The mixture was allowed to incubate at room temperature for another 16 hr, evaporated to dryness, and resuspended in 2 ml 1% triethylamine-water. The mixture was centrifuged, and the supernatant was purified via HPLC (Phenomenex C18, semi-prep; 5 min 0% B, 20 min 5% B, 25 min 10% B, 30 min 30% B, 40 min 80% B; A = water, B = acetonitrile, 2 ml/min).

The HPLC elution profile and mass spectrum of the product indicate that the product has undergone decarboxylation of the Ama sidechain ([@bib42]). It is known that acid and heat induce decarboxylation of the GE Ama sidechain, and that decarboxylated GE exhibits ∼1/20 the RNAP-inhibitory activity and antibacterial activity of GE ([@bib42]).

Yield: 3.5 mg; 18%.

MS (MALDI): calculated: *m/z* 777.80 (MH^+^); found: 778.20, 800.59 (M + Na^+^).

Synthesis of GE-rifamycin bipartite inhibitor: step 2, synthesis of {\[α-descarboxy-Ama\]GE}-NH-{rifamycin S} (compound 2 of [Figure 7C](#fig7){ref-type="fig"}) {#s4-25}
----------------------------------------------------------------------------------------------------------------------------------------------------------------

3-Bromo-rifamycin S (2.7 mg; 3.47 μmol; prepared as in [@bib41]), compound 1 (2.7 mg; 3.47 μmol; Example 1a) and triethylamine (0.5 μl; 3.47 μmol; Aldrich) were mixed together in 200 μl DMF and allowed to react for 18 hr at 25°C. The reaction mixture was quenched with 100 μl water, centrifuged, and the supernatant was purified via HPLC (Phenomenex C18, semi-prep; 0 min 10% B, 35 min 100% B; A = water, B = acetonitrile, 2 ml/min).

Yield: 1.51 mg; 30%.

MS (MALDI): calculated: *m/z* 1493.52 (M + Na^+^); found: 1494.22.

Synthesis of GE-rifamycin bipartite inhibitor: step 3, synthesis of {\[α-descarboxy-Ama\]GE}-NH-{RifSV} (compound 3 of [Figure 7C](#fig7){ref-type="fig"}; "RifaGE-3") {#s4-26}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Sodium ascorbate (2.38 mg; 12 μmol; Aldrich) in 25 μl water was added to compound 2 (0.600 mg; 0.4 μmol; Example 1b) in 100 μl water, mixed, and allowed to react for 10 min at 25°C. The product was isolated via HPLC (Phenomenex C18, analytical; 0' 10% B, 35′ 100% B; A = water, B = acetonitrile, 1 ml/min).

Yield: 0.1 mg; 17%.

MS (MALDI): calculated: m/z 1495.52 (M + Na+); found: 1495.71.
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(**A**) 'Doped' oligonucleotide primers used for saturation mutagenesis. (**B**) Chromosomal GE^R^ mutants in *E. coli* D21f2tolC: sequences and properties. (**C**) Chromosomal GE^R^ mutants in *S. pyogenes*: sequences and properties. (**D**) Chromosomal GE^R^ mutants in *E. coli* D21f2tolC: absence of cross-resistance to Rif. (**E**) Chromosomal Rif^R^ mutants in *E. coli* D21f2tolC: absence of cross-resistance to GE. (**F**) GE^R^ mutants from saturation mutagenesis: absence of cross-resistance to Sor, Stl, CBR703, Myx, and Lpm.
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